Institutes
Refine
Year of publication
- 2021 (667) (remove)
Document Type
- Article (618)
- Preprint (32)
- Conference Proceeding (11)
- Doctoral Thesis (6)
Language
- English (667) (remove)
Has Fulltext
- yes (667) (remove)
Is part of the Bibliography
- no (667)
Keywords
- SARS-CoV-2 (23)
- COVID-19 (20)
- inflammation (12)
- prostate cancer (9)
- autophagy (8)
- Epilepsy (7)
- survival (7)
- ADHD (6)
- breast cancer (6)
- radical prostatectomy (6)
- tumor microenvironment (6)
- Genetics (5)
- aging (5)
- apoptosis (5)
- children (5)
- endothelial cells (5)
- mortality (5)
- outcome (5)
- risk factors (5)
- Cancer (4)
- Heart failure (4)
- Immunotherapy (4)
- Neurology (4)
- ROS (4)
- Risk factors (4)
- acute myeloid leukemia (4)
- angiogenesis (4)
- chemotherapy (4)
- cirrhosis (4)
- epilepsy (4)
- extracellular matrix (4)
- gene therapy (4)
- hypoxia (4)
- iron (4)
- iron deficiency (4)
- oxidative stress (4)
- prevalence (4)
- stroke (4)
- targeted therapy (4)
- vaccination (4)
- 177Lu-PSMA-617 (3)
- Acute myeloid leukemia (3)
- Alcohol (3)
- Angiogenesis (3)
- Apoptosis (3)
- Biochemistry (3)
- Bipolar disorder (3)
- Cell biology (3)
- Diagnostic markers (3)
- EEG (3)
- Edema (3)
- Immunology (3)
- IntelliCage (3)
- Medical research (3)
- Melanoma (3)
- Microbiology (3)
- Molecular biology (3)
- Mortality (3)
- NK cells (3)
- Outcome (3)
- PSMA (3)
- Proteomics (3)
- Quality of life (3)
- Radiotherapy (3)
- Seizure (3)
- Surgery (3)
- Survival (3)
- VEGF (3)
- adverse events (3)
- biomarker (3)
- bladder cancer (3)
- cancer (3)
- data science (3)
- dentate gyrus (3)
- epidemiology (3)
- exosomes (3)
- external beam radiotherapy (3)
- fMRI (3)
- glioblastoma (3)
- haemophilia care (3)
- haemophilia treatment (3)
- immune cells (3)
- immunotherapy (3)
- influenza (3)
- liver (3)
- liver cirrhosis (3)
- lung cancer (3)
- macrophage polarization (3)
- macrophages (3)
- metastasis (3)
- metastatic prostate cancer (3)
- pediatric (3)
- proliferation (3)
- toll-like receptor (3)
- treatment (3)
- treatment centres (3)
- 3D printing (2)
- ALK (2)
- Acuris (2)
- Acute lymphoblastic leukemia (2)
- Adenocarcinoma (2)
- Age estimation (2)
- Anemia (2)
- Angiography (2)
- Ataxia-telangiectasia (2)
- Attitude (2)
- Autopsy (2)
- BAG3 (2)
- BCOR (2)
- BPH (2)
- Bacterial infection (2)
- Behavior (2)
- Blood (2)
- Blood loss estimation (2)
- Blow flies (2)
- Bone density (2)
- Bone marrow (2)
- Brain (2)
- Breast cancer (2)
- Burden of illness (2)
- CD14 (2)
- COVID 19 (2)
- CRM (2)
- CSM (2)
- Cancer-specific mortality (2)
- Cardiovascular diseases (2)
- Cell culture (2)
- Cesarean section (2)
- Chronic kidney disease (2)
- Cirrhosis (2)
- Collagen (2)
- Corona (2)
- DMEK (2)
- Dental implant (2)
- Depression (2)
- Dravet syndrome (2)
- ER stress (2)
- EWSR1 (2)
- Endocannabinoid (2)
- Endocrinology (2)
- Entscheidungsassistenz (2)
- Environmental support (2)
- Epidemiology and End Results (2)
- Fasting (2)
- Forensic medicine (2)
- Gene fusion (2)
- Gene regulation (2)
- Gleason score (2)
- Glioblastoma (2)
- Glucose (2)
- Health care (2)
- Healthcare costs (2)
- Human behaviour (2)
- Hypertension (2)
- Induction chemotherapy (2)
- Infection (2)
- Inflammation (2)
- Intensive care treatment (2)
- Intensive care units (2)
- Interleukin-6 (2)
- Ketogenic diet (2)
- Labor and delivery (2)
- Leptin (2)
- MRI (2)
- Machine learning (2)
- Medical consultation (2)
- Medical risk factors (2)
- Model (2)
- Multidetector computed tomography (2)
- NADH dehydrogenase (2)
- NADPH oxidase (2)
- NCCN (2)
- NF-κB (2)
- Neuroscience (2)
- Osteoporosis (2)
- PCR (2)
- Pandemic (2)
- Pathogenesis (2)
- Patient blood management (2)
- Patient needs (2)
- Patientenbedürfnisse (2)
- Pediatric (2)
- Penile cancer (2)
- Periodontal treatment (2)
- Person-Umwelt-Passung (2)
- Person-environment fit (2)
- Physical activity (2)
- Physiology (2)
- Platelet-rich fibrin (2)
- Point-of-care testing (2)
- Portal hypertension (2)
- Post-mortem interval (2)
- Pregnancy (2)
- Preterm birth (2)
- Prevalence (2)
- Prognostic tool (2)
- Prophylaxis (2)
- Prostate cancer (2)
- Pulmonary embolism (2)
- Radiation (2)
- Rare diseases (2)
- Research Article (2)
- SCC (2)
- SV2A (2)
- Sensitivity (2)
- Specificity (2)
- Spine (2)
- Squamous cell carcinoma (2)
- Status epilepticus (2)
- Suicide (2)
- Supported decision making (2)
- Surveillance (2)
- Systemic inflammation (2)
- Systemic therapy (2)
- TSC (2)
- Tomography (x-ray computed) (2)
- Tooth loss (2)
- Trauma (2)
- Treatment (2)
- Treatment outcome (2)
- Ultrasound (2)
- Undergraduate medical education (2)
- Unterstützung der Umwelt (2)
- Usability (2)
- Variant histology (2)
- Visual estimation (2)
- alcohol use disorder (2)
- anemia (2)
- animal experiments (2)
- antibiotic resistance (2)
- antiviral therapy (2)
- bibliometrics (2)
- biomarkers (2)
- biopsy cores (2)
- bleeding (2)
- bortezomib (2)
- brain cancer (2)
- cancer-specific mortality (2)
- cell cycle (2)
- cell migration (2)
- cerebrospinal fluid (2)
- cesarean section (2)
- child (2)
- childhood acute myeloid leukemia (2)
- chronic kidney disease (2)
- clinical trial (2)
- clinical trials (2)
- colon cancer (2)
- complexome profiling (2)
- computed tomography (2)
- contemporary (2)
- coronavirus (2)
- critical care (2)
- dexamethasone (2)
- diabetes (2)
- diabetes mellitus (2)
- diagnostic algorithm (2)
- drug resistance (2)
- efficacy (2)
- elderly (2)
- electrophysiology (2)
- epigenetics (2)
- epithelial to mesenchymal transition (2)
- ergonomics (2)
- executive function (2)
- extracellular vesicles (2)
- fibroblasts (2)
- follow-up (2)
- furcation involvement class III (2)
- fusion biopsy (2)
- heart (2)
- heart failure (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- homeostatic plasticity (2)
- innate immunity (2)
- intermediate risk (2)
- iron metabolism (2)
- kidney (2)
- kidney cancer (2)
- levetiracetam (2)
- lipocalin-2 (2)
- liver transplantation (2)
- lncRNA (2)
- localized prostate cancer (2)
- long-term tooth survival (2)
- lymph node dissection (2)
- machine learning (2)
- macrophage (2)
- magnetic resonance imaging (2)
- mast cells (2)
- metastatic castration-resistant prostate cancer (2)
- miRNA (2)
- microRNA (2)
- microglia (2)
- multiple sclerosis (2)
- ncRNA (2)
- neurocognitive (2)
- neuropathic pain (2)
- neutralizing antibodies (2)
- niche (2)
- oligomerisation (2)
- osteoarthritis (2)
- other-cause mortality (2)
- out-patient paediatrics (2)
- overall survival (2)
- oxidative phosphorylation (2)
- p53 (2)
- pain (2)
- patients (2)
- pediatric patients (2)
- pentose phosphate pathway (2)
- perception (2)
- periodontitis stage III and IV (2)
- pharmacokinetics (2)
- phosphorylation (2)
- platelets (2)
- pneumonia (2)
- portal hypertension (2)
- primary care (2)
- primary cilium (2)
- primary prostate cancer (2)
- questionnaire (2)
- radical prostatecomy (2)
- radiotherapy (2)
- receptor (2)
- refractory (2)
- regenerative medicine (2)
- relapse (2)
- residual myometrial thickness (2)
- respiratory chain (2)
- respiratory tract infection (2)
- salvage therapy (2)
- second-line (2)
- seizure (2)
- spine head (2)
- status epilepticus (2)
- strength training (2)
- stress (2)
- stress granules (2)
- supportive periodontal therapy (2)
- surgery (2)
- synaptic plasticity (2)
- synaptopodin (2)
- systematic biopsy (2)
- systemic antibiotics (2)
- thrombolysis (2)
- thrombosis (2)
- tissue engineering (2)
- tooth loss (2)
- triple-negative breast cancer (2)
- tumor necrosis factor (2)
- tumor-associated macrophages (2)
- tyrosine kinase inhibitors (2)
- ubiquitination (2)
- urological cancer (2)
- very high risk (2)
- working memory (2)
- Ärztliche Aufklärung (2)
- (sub-) luxation (1)
- 1-propanol (1)
- 2-AG (1)
- 2-Arachidonoyl glycerol (1)
- 2-deoxy-d-glucose (1)
- 26 LncRNA (1)
- 2′,3′-cGAMP (1)
- 3-year survival (1)
- 3D gait analysis (1)
- 3D printing using composite resin (1)
- 3D printing using zirconia (1)
- 3D rapid prototyping (1)
- 3T3-L1 mouse fibroblasts (1)
- 5-lipoxygenase (1)
- 8 weeks (1)
- ABCB5 (1)
- ACE inhibitor (1)
- ACLF (1)
- ADAM15 (1)
- ADCC (1)
- AGMO (1)
- AIDS (1)
- AKT (1)
- AKT signaling (1)
- ALD (1)
- ALDH2 (1)
- AML (1)
- AO-PCCF (1)
- APT-CEST (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- ATG3 (1)
- AU-rich element (1)
- Accidents (1)
- Acinetobacter baumannii (1)
- Acquired resistance (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute inflammation (1)
- Acute kidney failure (1)
- Acute kidney injury (1)
- Acute respiratory distress syndrom (1)
- Adiposity (1)
- Adults (1)
- Advanced stage (1)
- Adverse effects (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Affective Misattribution Procedure (1)
- Ag-RDT (1)
- Aganglionosis (1)
- Aging (1)
- Albumin (1)
- Algorithms (1)
- Alpha power (1)
- Alpha-fetoprotein (AFP) (1)
- Alzheimer's disease (1)
- Amblyopia (1)
- Amino acids (1)
- Amniotic fluid (1)
- Amphetamine (1)
- Analysis tool (1)
- Anandamide (1)
- Anemia management (1)
- Angiomyolipoma (1)
- Angststörungen (1)
- Animal disease models (1)
- Animal experiment (1)
- Animal models (1)
- Anti-seizure medication (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Antibody avidity (1)
- Anticonvulsant (1)
- Antimicrobial treatment (1)
- Antiretroviral therapy (1)
- Anwendbarkeit (1)
- Anxiety (1)
- Apoptotic cell death (1)
- Ara h2-specific IgE (1)
- Artificial intelligence (1)
- Asparaginase (1)
- Aspergillus (1)
- Astrocytoma (1)
- Ataxia telangiectasia (1)
- Atomoxetine (1)
- Attention (1)
- Attention Deficit Hyperactivity Disorder (ADHD) (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Autism (1)
- Autism Spectrum disorder (1)
- Autism spectrum disorder (1)
- Autologous biomaterial (1)
- Ayurveda (1)
- B cells (1)
- B-cell transcription factors (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BCORL1 (1)
- BCX7353 (1)
- BEACOPP (1)
- BMI (1)
- BMNC (1)
- BNT162b2 (1)
- BNT2b2 (1)
- BPO (1)
- BPTF (1)
- BRD4 (1)
- Back scan (1)
- Bacterial leakage (1)
- Barrier (1)
- Bartonella grahamii (1)
- Bartonella henselae (1)
- Bartonella schoenbuchensis (1)
- Basal ganglia (1)
- Beckwith–Wiedemann syndrome (1)
- Behandlungspfad (1)
- Behavioural ecology (1)
- Berotralstat (1)
- Bevacizumab (1)
- Big Five (1)
- Bio safety (1)
- Biofilm (1)
- Biological profile (1)
- Biomarker (1)
- Biomarkers (1)
- Biophysical models (1)
- Biophysics (1)
- Biopsy (1)
- Birth (1)
- Birth weight (1)
- Bleeding (1)
- Blood coagulation disorder (1)
- Blood loss calculator (1)
- Blood loss formula (1)
- Blood management (1)
- Blood plasma (1)
- Blood sampling (1)
- Blutungskontrolle (1)
- Body sway (1)
- Bone cement implantation syndrome (1)
- Bone diseases, Metabolic (1)
- Bone metastases (1)
- Bowel obstruction (1)
- Bradycardia (1)
- Brain metastasis (1)
- Brain tumor (1)
- Browsertool (1)
- Burkitt’s lymphoma (1)
- C-reactive protein (1)
- C1 inhibitor (1)
- CAD-CAM (1)
- CAD/ CAM crown (1)
- CAD/CAM crown (1)
- CAM (1)
- CAPON (1)
- CCC-2 (1)
- CD16 (1)
- CD34+ cell enumeration (1)
- CD36 (1)
- CD45RA Depletion (1)
- CD47 (1)
- CD62L (1)
- CD8+ T cells (1)
- CDH13 (1)
- CDK2 (1)
- CDK4/6 inhibitors (1)
- CDK9 (1)
- CEST EPI (1)
- CNDAC (1)
- COMP (1)
- COPD (1)
- COVID-19 pandemic (1)
- COVID-19 vaccination (1)
- COVID-19, Primary care (1)
- COVID‐19 (1)
- CRISPR/Cas (1)
- CRPC (1)
- CT (1)
- CT dual-energy computed tomography (1)
- CTLA-4 (1)
- Cabozantinib (1)
- Calcium (1)
- Calcium calmodulin kinase (1)
- Calliphoridae (1)
- Cancer genomics (1)
- Cancer survivors (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Cannabis (1)
- Cardiac biomarkers (1)
- Cardiac implantable electronic devices (1)
- Cardiac rehabilitation (1)
- Cardiac resynchronization therapy (1)
- Cardio-oncology (1)
- Cardiotoxicity (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular magnetic resonance (1)
- Carotid injury (1)
- Case report (1)
- Catumaxomab (1)
- Cell death (1)
- Cell division (1)
- Cell-based Assays (1)
- Cement gap (1)
- Ceramides (1)
- Checkpoint Inhibitor (1)
- Chikungunya (1)
- Chimeric Antigen Receptor (CAR) (1)
- Cholinergic (1)
- Chrna7 knockout (1)
- Circadian (1)
- Clinical Global Impression of Change (1)
- Clinical Trials and Observations (1)
- Clinical decision support systems (1)
- Clinical pathway (1)
- Clinical pharmacology (1)
- ClpB (1)
- Cochlear implantation (1)
- Cognitive dysfunction (1)
- Cohort studies (1)
- Colorectal cancer (1)
- Colorimetric blood loss estimation (1)
- Combined surgical therapy (1)
- Combustion (1)
- Complex decongestive therapy (1)
- Complicated stage (1)
- Complications (1)
- Computational models (1)
- Computational neuroscience (1)
- Computational science (1)
- Computed tomography, X-ray (1)
- Computer hardware (1)
- Computer science (1)
- Computer software (1)
- Computer-assisted diagnosis (1)
- Cone-beam computed tomography (1)
- Conometric connection (1)
- Consensus document (1)
- Constipation (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Continuous renal replacement therapy (1)
- Contrast agent (1)
- Corneal tomography (1)
- Corona virus (1)
- Coronary heart disease (1)
- Costs (1)
- Course (1)
- Covid-19 (1)
- Cre-recombinase (1)
- Crisis (1)
- Critical care (1)
- Cue-P3 (1)
- Culicidae (1)
- Custom-made mouthguard (1)
- Cyclin T1 (1)
- Cystatin C (1)
- DC-NK cell interaction (1)
- DCK (1)
- DNA integrity (1)
- DPPIV (1)
- Data Analysis (1)
- Data processing (1)
- Data reduction (1)
- Daubert criteria (1)
- Dead space (1)
- Decision support (1)
- Deep brain stimulation (1)
- Degradation (1)
- Dengue (1)
- Dentists (1)
- Developmental Biology (1)
- Dexamethasone (1)
- Diagnosis (1)
- Diagnostic algorithm (1)
- Diffusion magnetic resonance imaging (1)
- Diphtheria (1)
- Diptera (1)
- Direct measurement (1)
- Direct oral anticoagulation (1)
- Disease progression (1)
- Diseases (1)
- Dislocations of the knee (1)
- Dizygotic ectopic (1)
- Dopamine (1)
- Dose response (1)
- Droplets (1)
- Drospirenon (1)
- Drug addiction (1)
- Drug resistance (1)
- Drug targets (1)
- Drug therapy (1)
- Dual-energy computed tomography (1)
- Dynamic MRI (1)
- Dysfunctional social assumptions (1)
- D’Amico classification (1)
- EBRT (1)
- ECMO (1)
- EET (1)
- EHL concentrates (1)
- ENIGMA (1)
- EP300 (1)
- EQ5D5L (1)
- EQA scheme (1)
- ER-phagy (1)
- ERAL1 (1)
- ERK inhibitor (1)
- ERK1/2 signaling (1)
- ESBL (1)
- Early setting (1)
- Eccentric fixation (1)
- Ectopic pregnancy (1)
- Effective half-life (1)
- Efficacy (1)
- Efficiency (1)
- Electric stimulation (1)
- Elternurteil (1)
- Emergency room (1)
- Ena/VASP proteins (1)
- Encephalopathy (1)
- Endocrine system and metabolic diseases (1)
- Endocrine therapy (1)
- Endothelial cells (1)
- Endothelial progenitor cells (1)
- Energy (1)
- Engraftment (1)
- Enterobacterales (1)
- Environmental biotechnology (1)
- Environmental sciences (1)
- EpCAM positive tumor (1)
- Ephrin-B2–EphB4 (1)
- Epigenetics (1)
- Epileptische Anfälle (1)
- Epileptischer Anfall (1)
- Epithelialization (1)
- Epsilon (1)
- Estimated glomerular filtration rate (1)
- Event related potentials (1)
- Everolimus (1)
- Evidence-based (1)
- Evidenzbasiert (1)
- Ewing sarcoma (1)
- Ewing-like (1)
- Exercise (1)
- Exercise training (1)
- Exoscope (1)
- Exosomes (1)
- Expansion (1)
- Expectation violation (1)
- External beam radiotherapy (1)
- Extracellular matrix (1)
- Extracellular vesicles (1)
- Exudates and transudates (1)
- FABP (1)
- FAM134 (1)
- FFP3 respirator (1)
- FGFR (1)
- FOXO1 (1)
- FOXO3 (1)
- FXR (1)
- Facial nerve (1)
- Falls (1)
- Feasibility studies (1)
- Fendrr (1)
- Fertility counseling (1)
- Filariasis (1)
- Fluid overload (1)
- Fluorescence (1)
- Forensic entomology (1)
- Forensic experts (1)
- Forensic pathology (1)
- Frontobasal (1)
- Fuchs endothelial dystrophy (1)
- G2A (1)
- GD2 (1)
- GEMs (1)
- GFR (1)
- GIIb/IIIa-receptor (1)
- GMP (1)
- GPCR (1)
- GPR4 (1)
- GTP cyclohydrolase (1)
- Ganglionic (1)
- Gan–Dou–Fu–Mu decoction (GDFMD) (1)
- Gastric motility (1)
- Gastroenterology (1)
- Gender (1)
- Gene expression (1)
- General Practitioner (1)
- Genetic techniques (1)
- Genetics research (1)
- Genome editing (1)
- Gestagen-Monopräparate (1)
- Gezielte Therapie (1)
- Glaucoma (1)
- Gleason Grade Group (1)
- Gleason grade group (1)
- Glioblastoma survival (1)
- Glomerulosclerosis (1)
- Glycolysis (1)
- Grading (1)
- Graft (1)
- Graft quality (1)
- Granulocytes (1)
- Graves’ disease (1)
- Gravimetric method (1)
- Guidance (1)
- Guide profession (1)
- Gut (1)
- H1N1 (1)
- HAE (1)
- HARS2 (1)
- HBV (1)
- HCC (1)
- HCC marker (1)
- HDR-brachytherapy (1)
- HER2 (1)
- HIV (1)
- HIV protease inhibitors (1)
- HL7 FHIR (1)
- HLA antibodies (1)
- HNSCC (1)
- HOLEP (1)
- HOTAIR (1)
- HPO (1)
- HPV-positive OPSCC (1)
- HRCT (1)
- HSC (1)
- HSP (hereditary spastic paraplegia) (1)
- HVPG (1)
- Haematologic diseases (1)
- Haemophilia (1)
- HeLa cells (1)
- Head and neck cancer (1)
- Health care workers (1)
- Health services (1)
- Health surveys (1)
- Healthcare resource utilisation (1)
- Healthcare resource utilization (1)
- Healthy adults (1)
- Healthy men (1)
- Heart (1)
- Heart transplantation (1)
- Heartrate (1)
- Hematologic adverse events (1)
- Hematopoietic stem cell (1)
- Hematotoxicity (1)
- Hepatic stellate cell (1)
- Hepatocellular carcinoma (1)
- Hepatocellular carcinoma (HCC) (1)
- Hereditary angioedema (1)
- Herniated disk (1)
- Heterotopic pregnancy (1)
- Hierarchical drift-diffusion modeling (1)
- High altitude (1)
- High-risk prostate cancer (1)
- Himalayas (1)
- Hip hemiarthroplasty (1)
- Hirschsprung disease (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- HoLEP (1)
- Hormone receptor positive breast cancer (1)
- Hydromineral (1)
- Hymenoptera venom allergy (1)
- IAP (1)
- ICG (1)
- IFN-β (1)
- IL-17A (1)
- IL-1b (1)
- IL-33 (1)
- INR (1)
- IPSS (1)
- ISR (1)
- IgA deficiency (1)
- Ileostomy (1)
- Ileus (1)
- Image processing (1)
- Immune cells (1)
- Immune checkpoint inhibitors (1)
- Immune complex vasculitis (1)
- Immune paralysis (1)
- Immune status (1)
- Immunodeficiency (1)
- Immunogenetics (1)
- Immunoglobulins (1)
- Immunohistochemistry (1)
- Immunophenotyping (1)
- Immuno‑histochemistry (1)
- Implantable cardioverter-defibrillator (1)
- Implicit Processing (1)
- Implicit Association Test (1)
- In vivo electrophysiology (1)
- Inactivation (1)
- IncX (1)
- Incidence rate (1)
- Incontinence (1)
- Indication for fertility preservation (1)
- Indirect treatment comparison (ITC) (1)
- Indocyanine green (1)
- Indonesia (1)
- Injuries (1)
- Injury (1)
- Intention attribution (1)
- Interleukin-10 (1)
- International normalized ratio (1)
- Internet-based therapy (1)
- Interpretation Bias (1)
- Intervention (1)
- Intervertebral disc displacement (1)
- Interviews (1)
- Intimal-medial thickness (1)
- Intraoperative blood salvage (1)
- Intrinsic resistance (1)
- Intubation (1)
- Isoflurane (1)
- Isothermal amplification (1)
- Ixodes ricinus (1)
- JAK2V617F (1)
- KCCQ (1)
- KCNQ1 (1)
- KLHL11 (1)
- KPS (1)
- Kallikrein inhibitor (1)
- Kappa (1)
- Keap1-Nrf2 (1)
- Ki-67 (1)
- Kindes- und Jugendalter (1)
- Knee surgery (1)
- Kontrazeption (1)
- LARS2 (1)
- LDHB (1)
- LEOSS (1)
- LPS (1)
- LQTS (1)
- LSCC (1)
- LSEC (1)
- LanCL2 (1)
- Lasers (1)
- Lateral flow antigen testing (1)
- Lateral flow immunoassay (1)
- Learning and memory (1)
- Lee type, functional outcome (1)
- Legal medicine (1)
- Leigh syndrome (1)
- Leishmaniasis (1)
- Lemperle (1)
- Leukemia (1)
- Leukocyte depletion filter (1)
- Lipedema (1)
- Liposuction (1)
- Liver Transplantation (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Local therapy (1)
- Long non-coding RNA (1)
- Long non-coding RNAs (1)
- Low grade glioma (1)
- Low-molecular-weight heparin (1)
- Low-virulent infection (1)
- Lung neoplasms (1)
- Lymphocyte subpopulations (1)
- Lymphopenia Mortality (1)
- MDD (1)
- MEIS (1)
- MEK inhibitor (1)
- MLKL (1)
- MN1 (1)
- MRI-negative epilepsy (1)
- MTOR inhibitor (1)
- MTRasym (1)
- MVPA (1)
- MYC (1)
- MYCN amplification (1)
- Macrophage polarization (1)
- Magnetic resonance imaging (1)
- Major depressive disorder (1)
- Malaria (1)
- Malignant meningioma (1)
- Manchester scar scale (1)
- Marginal integrity (1)
- Masking effect (1)
- Mastoiditis (1)
- Matching-adjusted indirect comparison (MAIC) (1)
- Materials science (1)
- Mathematical functions (1)
- Maxillofacial reconstruction (1)
- Maxillofacial trauma (1)
- Medical history (1)
- Meersseman test (1)
- Meningioma (1)
- Mental health and psychiatry (1)
- Mental health therapies (1)
- Metabolic diseases (1)
- Metabolic dysfunction (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metalloproteinases (1)
- Metastasis-directed therapy (1)
- Metastatic castration-resistant prostate cancer (1)
- Methanol (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Method validation (1)
- Methylphenidate (1)
- MiSpEx-network (1)
- Micro computed tomography (1)
- MicroRNAs (1)
- Microbiology and Infectious Disease (1)
- Microgap (1)
- Microwave ablation (1)
- Minimal invasive dentistry (1)
- Mitochondrial ROS (1)
- Mitochondrial dysfunction (1)
- Mitosis (1)
- Molecular Biology (1)
- Molecular diagnostics (1)
- Molecular neuroscience (1)
- Monoclonal antibody (mAb) (1)
- Monocytes (1)
- Mosquito (1)
- Motivation (1)
- Mountain (1)
- Multianalyte detection (1)
- Multidrug-resistant organisms (1)
- Multiligament instability (1)
- Multivariate analysis (1)
- Musculoskeletal abnormalities (1)
- Musculoskeletal problems (1)
- Musculoskeletal system (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myeloid Neoplasia (1)
- Myiasis (1)
- Myocardial infarction (1)
- Myocardial remodeling (1)
- N471D strumpellin knock-in mice (1)
- N501Y (1)
- NAFLD (1)
- NASH (1)
- NET (1)
- NFkB (1)
- NK cell subsets (1)
- NK-92 (1)
- NO (1)
- NOS-I (1)
- NOS1AP (1)
- NSBB (1)
- NURF (1)
- Natural killer cells (1)
- Necroptosis (1)
- Necrotizing enterocolitis (1)
- Negligence (1)
- Nephrectomy (1)
- Neural stem cells (1)
- Neurodegeneration (1)
- Neuroepithelial (1)
- Neuroepithelial tumor (1)
- Neurofeedback (1)
- Neurofilament light chain (1)
- Neuroligins (1)
- Neurooncology (1)
- Neuropilin (1)
- Neurotoxicity (1)
- Neurovascular damage (1)
- Next-generation sequencing (1)
- NfL (1)
- Niche (1)
- Nicotine (1)
- Nitric oxide (1)
- Nonaerosolizing treatment (1)
- Nontuberculous mycobacteria (1)
- Noradrenergic (1)
- Norepinephrine (1)
- Nox4 (1)
- Nrf-2 (1)
- Nrf2 (1)
- Nutrition (1)
- OA (1)
- OGR1 (1)
- OHIP-G14 (1)
- OHRQoL (1)
- ORP (1)
- OSCE (1)
- OXA-48 (1)
- OXA-484 (1)
- OXPHOS (1)
- Obstetrics and gynecology (1)
- Occlusion treatment (1)
- Occupational health (1)
- Older patient (1)
- Olfactory groove meningioma (1)
- Olfactory system (1)
- Oligodendroglioma (1)
- Oligometastatic (1)
- Omega lipids (1)
- Oncogenes (1)
- Oncology (1)
- Online Survey (1)
- Opinion (1)
- Opioids (1)
- Opportunistic infections (1)
- Oral food challenge (1)
- Oral immunotherapy (OIT) (1)
- Oral therapy (1)
- Orbital fracture (1)
- Organ failure (1)
- Organ injury (1)
- Orthodontic tooth movement (1)
- Osteoporotic fractures (1)
- Otorhinolaryngological (1)
- Outcomes (1)
- Outcomes research (1)
- Outpatients (1)
- Overweight (1)
- Oxidative phosphorylation (1)
- P2X7 receptor (1)
- PAC-1 (1)
- PAD-test (1)
- PAPR (1)
- PATZ1 (1)
- PBSC (1)
- PBX (1)
- PD-1 (1)
- PD-L1 (1)
- PLAGL1 (1)
- PMA (1)
- PML (1)
- PMMA (1)
- POCT (1)
- POR (1)
- PPAR-γ (1)
- PRF (1)
- PRNT (1)
- PRRT (1)
- PSA (1)
- PTEN inducible kinase 1 (1)
- PTM (1)
- Pacemaker (1)
- Pain (1)
- Pain management (1)
- Palacos reaction (1)
- Pandemie (1)
- Parenteral nutrition (1)
- Parkinson's disease (1)
- Parkinson’s disease (1)
- Particulates (1)
- Pathogens (1)
- Pathology (1)
- Pathophysiology (1)
- Patient manikins (1)
- Patient perspective (1)
- Patient preference (1)
- Patterns of care (1)
- Pediatric oncology (1)
- Pediatric stem cell transplantation (1)
- Pediatric surgery (1)
- Per1−/−-mice (1)
- Peri-implant disease (1)
- Peritoneal macrophages (1)
- Peritumoural oedema (1)
- Peri‑implantitis (1)
- Persistence SARS-CoV-2 antibodies (1)
- Personal protective equipment (1)
- Personalisierte translationale Therapie (1)
- Personalized medicine (1)
- Phagocytosis (1)
- Phantoms (imaging) (1)
- Pharmacokinetics (1)
- Pharmacology (1)
- Pharmacotherapy (1)
- Phase 3 (1)
- Phase 3 trial (1)
- Phenylketonuria (PKU) (1)
- Physical self-perception (1)
- Play (1)
- Pleasure (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Podospora anserina (1)
- Point of care (1)
- Point-of-care wound diagnostics (1)
- Poly-Pore (1)
- Polypharmacy (1)
- Population dynamics (1)
- Portal veins (1)
- Post mortem examination (1)
- Post-cesarean (1)
- Post-offence drinking (1)
- Post-thaw recovery (1)
- Post-traumatic stress disorder (1)
- Postmortem (1)
- Postmortem interval (1)
- Posture analysis (1)
- Potassium iodide (1)
- Powered air-purifying respirator (1)
- Pre-analytics (1)
- Preclinical research (1)
- Prediction of locoregional recurrence (1)
- Predictive coding (1)
- Predictive markers (1)
- Predictive model (1)
- Prevention (1)
- Preventive medicine (1)
- Primary care (1)
- Primary health care (1)
- Primary molars (1)
- Primärversorgung (1)
- Principal component analysis (1)
- Prisoners (1)
- Prisons (1)
- Probability density (1)
- Probability distribution (1)
- Proficiency testing (1)
- Prognostic markers (1)
- Prognostic models (1)
- Protease inhibitor therapy (1)
- Proximal (1)
- Pseudomonas aeruginosa (1)
- Pseudophakia (1)
- Psoriasis (1)
- Psoriatic arthritis (1)
- Psychiatric disorders (1)
- Psychiatry (1)
- Psychology (1)
- Pyogenic spondylodiscitis (1)
- Python (1)
- Qualitative study (1)
- Quality control (1)
- RARP (1)
- RAS pathway (1)
- RCT (1)
- RET (1)
- RGAG1 (1)
- RMS (1)
- RNA (1)
- RNA sequencing (1)
- RNA therapeutics (1)
- RNA therapy (1)
- RNA-binding protein (1)
- RNA-sequencing (1)
- RNAP II (1)
- RND (1)
- RNF4 (1)
- ROC analyses (1)
- ROC-Analysen (1)
- ROS1 (1)
- RT-PCR-detection (1)
- Race (1)
- Radiation Oncology (1)
- Radiation necrosis (1)
- Radical prostatectomy (1)
- Radiochemotherapy (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Radiology (1)
- Radiomics (1)
- Radiosurgery (1)
- Ramucirumab (1)
- Randomisation (1)
- Randomized Controlled Trial (1)
- Randomized controlled trial (1)
- Reactive oxygen species (1)
- Ready-made mouthguard (1)
- Real-time MRI (1)
- Real-time polymerase chain reaction (PCR) tests (1)
- Rectal cancer (1)
- Redoxin (1)
- Refractive changes (1)
- Region (1)
- Registry (1)
- Renal cell carcinoma (1)
- Rescue medication (1)
- Resection (1)
- Residual myometrial thickness (1)
- Respiratory distress syndrome (1)
- Respiratory infections (1)
- Response control (1)
- Restenosis (1)
- Resting-state (1)
- Retrospective study (1)
- Reward (1)
- Rhabdomyoma (1)
- Rho-kinase (1)
- Ridge preservation (1)
- Riftia pachyptila (1)
- Risk factor (1)
- Risk stratification (1)
- Roussel Uclaf Causality Assess- ment Method (RUCAM) (1)
- S1P lyase (1)
- S63845 (1)
- SAH (1)
- SAMHD1 (1)
- SARS CoV 2 (1)
- SARS-CoV-2 testing (1)
- SARS-CoV‑2 (1)
- SCCHN (1)
- SCD14 (1)
- SEC-ICP-DRC-MS (1)
- SEER (1)
- SELEX (1)
- SF-36 (1)
- SGPL1 (1)
- SGPL1 knockout cell line (1)
- SH-SY5Y neuroblastoma cells (1)
- SIRPalpha (1)
- SIRT1 (1)
- SKALE score (1)
- SLC6a3 (1)
- SLC7A11 (1)
- SPG8 (1)
- SUMO (1)
- Safety (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Sandfly (1)
- Sapacitabine (1)
- Sarcoma (1)
- Satisfaction (1)
- Scheimpflug imaging (1)
- Schizophrenia (1)
- Sclerotic glomeruli (1)
- Screeningfragebogen (1)
- Seasonal variation (1)
- Sedation (1)
- Sedatives (1)
- Seizures (1)
- Self-esteem (1)
- Sequencing (1)
- Short bowel syndrome (1)
- Side effect (1)
- Silver diamine fluoride (1)
- Simulated patients (1)
- Simulation training (1)
- Single-cell RNA sequencing (1)
- Skeletal health (1)
- Skull base (1)
- Slow Cortical Potentials, SCP (1)
- Smac mimetics (1)
- Smoking habits (1)
- Social Phobia (1)
- Social cognition (1)
- Social decision-making (1)
- Social neuroscience (1)
- Sociodemographic characteristics (1)
- Socket healing (1)
- Socket preservation (1)
- Soft tissue healing (1)
- Software (1)
- Solar insolation (1)
- Sonication (1)
- Sonography (1)
- Spinal fractures (1)
- Spinal surgery (1)
- Sport (1)
- Stability (1)
- Standard value (1)
- Standardization (1)
- Static MRI (1)
- Stem cell dose (1)
- Stem cell enumeration (1)
- Stereotactic ablative body radiotherapy (1)
- Stimulant (1)
- Sting challenge (1)
- Structured written feedback (1)
- Subependymal giant cell astrocytoma (1)
- Sudden Cardiac Death (SCD) (1)
- Suicidality (1)
- Sunlight (1)
- Superficial vein thrombosis (1)
- Supratentorial (1)
- Surgical blood loss (1)
- Surgical site infection (1)
- Sustained attention (1)
- Symmetrical blocked occlusion (1)
- Synaptic organizer (1)
- Synaptic transmission (1)
- Synaptosomal preparation (1)
- Syndecan-1 (1)
- Synthetic biology (1)
- Syrian hamster (1)
- Systematic review (1)
- T-cell development (1)
- T-cell receptor (TCR) (1)
- T-cells (1)
- TACE (1)
- TAM (1)
- TAVI (1)
- TDAG8 (1)
- TGF-β1 (1)
- TGFB-induced factor homeobox 1 (1)
- TGIF (1)
- TIPS (1)
- TLR4 (1)
- TME (1)
- TMT (1)
- TRAIL (1)
- TRP2 (1)
- TRPM8 (1)
- TRPV4 (1)
- TSP-4 (1)
- TTFields (1)
- TURP (1)
- TWNK (1)
- Taekwondoka (1)
- Tailored therapy (1)
- Tar (1)
- Targeted therapy (1)
- Telemedicine (1)
- Temozolomide (1)
- Tempo-parietal junction (1)
- Temporomandibular joint (1)
- Temporomandibular joint dysfunction (1)
- Tetanus (1)
- Tetrahydrobiopterin (1)
- Theft (1)
- Therapeutic anticoagulation (1)
- Thermogenesis (1)
- Thorax (1)
- Thyroid (1)
- Time of death (1)
- Time trend (1)
- Tobacco (1)
- Tomography (1)
- Tooth segmentation (1)
- Traditional Chinese Medicine (TCM) (1)
- Traditional Indian Medicine (1)
- Trajectories (1)
- Transcranial direct current stimulation (1)
- Transcription (1)
- Transcriptomics (1)
- Transdifferentiation (1)
- Transfusion (1)
- Translation (1)
- Translational research (1)
- Transplant logistics (1)
- Transplantation Centers (1)
- Travel times (1)
- Trisomy 21 (1)
- Troponin (1)
- Tuberous sclerosis complex (1)
- Tumor cell (1)
- Type three hypersensitivity (1)
- Tyrosine kinase inhibitor (TKI) (1)
- Tyrosinemia (1)
- UTUC (1)
- Ulixertinib (1)
- Understanding (1)
- Undiagnosed patients (1)
- Upper airway infection (1)
- Upper body posture (1)
- Urethral cancer (1)
- Uterus (1)
- VEGF receptor 2 internalization and signaling (1)
- VEGF receptors (1)
- VRE (1)
- Vaccine (1)
- Vagus nerve (1)
- Vagus nerve stimulation (1)
- Vascular endothelial growth factor (VEGF) (1)
- Ventilators (1)
- Video rasterstereography (1)
- Virtual noncalcium reconstructions (1)
- Virus trapping (1)
- Visual quality (1)
- WASH complex subunit 5 (1)
- WIPI2 (1)
- WIPI2b (1)
- Weight distribution (1)
- White blood cells (1)
- White matter hyperintensity (1)
- Wilson disease (WD) (1)
- Wnt (1)
- Working memory capacity (1)
- Wound healing (1)
- Wounds and injuries (1)
- X-ray computed (1)
- Yoga (1)
- Zika Virus (1)
- Zika fever (1)
- Zymosan-induced peritonitis (1)
- ablation (1)
- abscisic acid (1)
- abscopal effect (1)
- acetaminophen (1)
- acne inversa (1)
- acoustic radiation force impulse (1)
- action (1)
- activated factor XIII (1)
- acute decompensation (1)
- acute pain (1)
- acute stroke care (1)
- adaptation (1)
- adenosine (1)
- adhesion (1)
- adipocytes (1)
- adipose-derived stromal/stem cells (1)
- adjuvant chemotherapy (1)
- adolescence (1)
- adolescent (1)
- adult (1)
- advanced melanoma (1)
- adversity (1)
- age (1)
- aged (1)
- agent-based models (1)
- agility (1)
- agreeableness (1)
- air abrasive (1)
- allogeneic hematological stem cell transplantation (1)
- allogeneic stem cell transplant (1)
- allostasis (1)
- alpha power (1)
- alpha-synuclein (1)
- alpha7 nicotinic acetylcholine receptor (1)
- amide proton transfer (1)
- amyotrophic lateral sclerosis (1)
- aneurysm (1)
- animal model (1)
- anorectal malformation (1)
- anti-neural autoantibodies (1)
- antiadhesive composites (1)
- antibacterial composites (1)
- antibiotic prophylactic therapy (1)
- antibiotic prophylaxis (1)
- antibiotics (1)
- anticipation (1)
- anticoagulation (1)
- antiepileptic drug (1)
- antihelix shaping (1)
- antimicrobial stewardship (1)
- antiviral signaling (1)
- anxiety (1)
- anxiety disorders (1)
- aortic root replacement (1)
- aortic valve repair (1)
- aortic valve stenosis (1)
- aortic valve-sparing (1)
- aphrodisin (1)
- apical constriction (1)
- apical polarity (1)
- aptamer (1)
- aptamer modeling (1)
- arterial stiffness (1)
- articular cartilage (1)
- artifacts (1)
- artificial feeding (1)
- artificial intelligence (1)
- artificial intelligence (AI) (1)
- assembly (1)
- assembly factor (1)
- asthma (1)
- asymptomatic temporal encephaloceles (1)
- at-risk mental state (1)
- ataxia (1)
- atopic dermatitis (1)
- atrial fibrillation (1)
- attachment (1)
- attention (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory (1)
- auditory cortex (1)
- augmentation (1)
- autism (1)
- autoantibodies (1)
- autobiographical memories (1)
- autogenous tooth roots (1)
- autoimmune encephalitis (1)
- autoimmune-mediated psychosis (1)
- automatic scene classification (1)
- autophagy inhibition (1)
- azacitidine (1)
- bacteremia (1)
- bacteria (1)
- bacterial leakage (1)
- bacterial viability (1)
- bacteriophages (1)
- ball (1)
- basilar artery occlusion (BAO) (1)
- bats (1)
- behavioral inhibition (1)
- behavioural rhythms (1)
- benfooxythiamine (1)
- best medical treatment (1)
- beta-band activity (1)
- beta-lactamases (1)
- bibliometric analysis (1)
- bilateral (1)
- bile (1)
- bile acids (1)
- binocular vision (1)
- biochemical relapse free survival (1)
- biologization (1)
- bladder neck stenosis (1)
- blood cell mutations (1)
- blood coagulation (1)
- blood concentrates (1)
- blood culture (1)
- blood transfusion (1)
- blood-brain barrier (1)
- bloodstream infections (1)
- body plethysmography (1)
- bone (1)
- bone augmentation (1)
- bone barrow (1)
- bone regeneration (1)
- bone-regeneration (1)
- bowel dysfunction (1)
- brachytherapy (1)
- brain disorders (1)
- brain imaging (1)
- brain infection (1)
- brain metastases (1)
- cAMP (1)
- cGMP (1)
- callous-unemotional traits (1)
- calretinin (1)
- cancer cell metabolism (1)
- cancer immunotherapy (1)
- cancer metastases (1)
- cancer specific survival (1)
- cancer surveillance (1)
- cancer therapy (1)
- cancer treatment (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabinoid receptors (1)
- carbapenem resistance (1)
- carbapenemases (1)
- cardiac differentiation (1)
- cardiac magnetic resonance (1)
- cardiac regeneration (1)
- cardiac reprogramming (1)
- cardiocerebral resuscitation (1)
- cardiomyocyte apoptosis (1)
- cardiomyocyte proliferation (1)
- cardiomyocytes (1)
- cardiopulmonary resuscitation (1)
- cardiovascular disease (1)
- caregivers (1)
- cartilage (1)
- castration resistance (1)
- cell barrier integrity (1)
- cell culture (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell lines (1)
- cell proliferation regulating inhibitor of protein phosphatase 2A (1)
- cellular therapies (1)
- central nervous system (1)
- central spasticity (1)
- ceramides (1)
- cerebral imaging (1)
- cerebral ischemia (1)
- cerebral metastasis (1)
- cerebral palsy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- cervical cancer (1)
- cetuximab (1)
- chaperone-mediated autophagy (1)
- chemokines (1)
- chemoradiotherapy (1)
- childhood cancer (1)
- children and adolescents (1)
- cholesterol (1)
- cholinergic system (1)
- chronic (1)
- chronic granulomatous disease (1)
- chronic hepatitis C (1)
- chronic inflammation (1)
- classical Hodgkin lymphoma (1)
- classification (1)
- clindamycin (1)
- clinical decision-making (1)
- clinical high at-risk mental state (1)
- clinical isolates (1)
- clinical research (1)
- clinical stage (1)
- clinical teaching (1)
- clinically important restrictions and symptoms (1)
- clonal haematopoiesis (1)
- cluster analysis (1)
- cluttering (1)
- co-infection (1)
- cochlear implant (1)
- cochlear implants (1)
- collagen (1)
- collagen membranes (1)
- collective cell migration (1)
- colorectal cancer (1)
- combined modality therapy (1)
- comorbidities (1)
- complementary medicine (1)
- complete response (1)
- complex systems (1)
- compound screen (1)
- computational knowledge-discovery (1)
- computer-assisted (1)
- concordance (1)
- conduct disorder (1)
- confinement (1)
- congenital diaphragmatic hernia (1)
- congenital disorders of autophagy (1)
- conical coupling (1)
- conometric connection (1)
- consensus (1)
- conservative dentistry (1)
- constipation (1)
- contraception (1)
- control of menstrual bleeding (1)
- convulsive seizures (1)
- coping (1)
- core expression (1)
- corona virus (1)
- coronally advanced flap (1)
- corticosteroids (1)
- cost-effective (1)
- criteria (1)
- critical-size defect (1)
- critically ill patients (1)
- cross-linking (1)
- curcumin (1)
- cyclic nucleotide analogues (1)
- cyclic nucleotide binding proteins (1)
- cycling (1)
- cyclooxygenase-2 (1)
- cytochrome P450 enzymes (1)
- cytochrome P450 reductase (1)
- cytokines (1)
- cytotoxic T lymphocyte (1)
- dance teacher (1)
- data quality (1)
- data repositories (1)
- data sharing (1)
- death rates (1)
- decompressive craniectomy (1)
- default mode network (1)
- degradation (1)
- delayed diagnosis (1)
- delivery mode (1)
- delta (1)
- dendrite morphogenesis (1)
- dendritic cells (1)
- dengue vector (1)
- dental assistant (1)
- dental education (1)
- dental implant (1)
- dental school (1)
- dental treatment concept (1)
- dentist (1)
- dentist’s chair design (1)
- depth perception (1)
- desensitization (1)
- development (1)
- diabetes complication (1)
- diabetic nephropathy (1)
- diagnosis (1)
- diet (1)
- diffuse marrow involvement (1)
- digital medicine (1)
- digital one-piece casting (1)
- digital pressing technology (1)
- digital workflow (1)
- dihydrocannabidiol (1)
- diphtheria toxin (1)
- direct-acting antiviral (DAA) treatment (1)
- discontinuation (1)
- disease progression (1)
- dislocation (1)
- disordered iron metabolism (1)
- dobutamine stress (1)
- docetaxel (DX) resistance (1)
- dopamine transporter (1)
- dorsal attention network (1)
- double immune checkpoint inhibition (1)
- downgrading (1)
- doxycycline (1)
- drinking (1)
- drospirenone (1)
- drug (1)
- drug–drug interactions (1)
- drug–gene interactions (1)
- drug–g–gene interactions (1)
- dual-energy (1)
- dynamic causal modeling (1)
- dynamic system (1)
- early onset (1)
- early-onset prostate cancer (1)
- echo planar imaging (1)
- edentulous (1)
- efferocytosis (1)
- efflux pump (1)
- egg sampling (1)
- elastin (1)
- electrical coupling (1)
- electroanatomical mapping (1)
- electrode design (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- electrolytic cleaning (1)
- electron transfer (1)
- element speciation (1)
- emergency care (1)
- emicizumab (1)
- endodontic curriculum (1)
- endodontic education (1)
- endodontics (1)
- endothelial dysfunction (1)
- endourology (1)
- endovascular treatment (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- enzyme activity assay (1)
- epidermal growth factor receptor (1)
- epilepsy surgery (1)
- erastin (1)
- erythropoiesis (1)
- essential thrombocythemia (ET) (1)
- ethanol (1)
- everolimus (1)
- executive functions (1)
- exercise (1)
- expert witness statement (1)
- extraskeletal (1)
- eye movements (1)
- fMLP (1)
- factor XIII (1)
- faecal microbiota transfer (1)
- fall (1)
- famotidine (1)
- fasting insulin (1)
- fat grafting (1)
- fatty acid synthesis (1)
- fecal incontinence (1)
- fecal microbiota transfer (1)
- females (1)
- fenfluramine (1)
- ferric carboxymaltose (1)
- ferric derisomaltose (1)
- ferroportin (1)
- ferroptosis (1)
- ferumoxytol (1)
- fibrinolysis (1)
- fibrosis (1)
- first-time shoulder dislocation (1)
- flow cytometry (1)
- fondaparinux (1)
- fracture strength (1)
- fracture strength equation (1)
- frontotemporal dementia (1)
- full-arch restoration (1)
- function (1)
- functional connectome acute (1)
- functional magnetic resonance imaging (1)
- functional outcome (1)
- fungal sugar (1)
- fusion (1)
- fusion kinase (1)
- gait symmetry (1)
- gargle lavage (1)
- gastrointestinal stromal tumours (1)
- gender (1)
- genetic diversity (1)
- genetic variants (1)
- genetically caused iron imbalance (1)
- genotype G (1)
- geriatrics (1)
- gingival recession therapy (1)
- glecaprevir (1)
- glioma (1)
- glioma microenvironment (1)
- global health (1)
- glucose-6-phosphate dehydrogenase (1)
- glucosylceramides (1)
- glycoproteins (1)
- gp100 (1)
- graft-vs-host disease (1)
- granule polarization (1)
- graphic 3D models (1)
- great height (1)
- grisel syndrome (1)
- growth (1)
- growth inhibition (1)
- guided bone regeneration (1)
- guideline (1)
- haNK (1)
- haemophilia (1)
- harmonization (1)
- hatching (1)
- head and neck neoplasms (1)
- health database (1)
- health information interoperability (1)
- health-relatedquality of life (1)
- healthy control (1)
- hematotoxicity (1)
- hemorrhage (1)
- herb-induced liver injury (HILI) (1)
- heterogeneity (1)
- high risk (1)
- high-altitude adaptation (1)
- high-altitude pulmonary hypertension (1)
- high-fat-diet (1)
- high-risk (1)
- high-risk neuroblastoma (1)
- hip osteoarthritis (hip OA) (1)
- hippocampus (1)
- histamine (1)
- histopathological growth pattern (1)
- homeodomain protein (1)
- homeostasis (1)
- hospital admission (1)
- host-microbe interaction (1)
- human allogeneic hematopoietic cell transplantation (1)
- human behaviour (1)
- human factors (1)
- human intestinal microbiota (1)
- human olfaction (1)
- human subjects (1)
- humans (1)
- hybrid materials (1)
- hybrid production (1)
- hydrogen peroxide (1)
- hypersensitivity (1)
- hypobaric hypoxia (1)
- hypophosphatemia (1)
- hypoxia inducible factor 1 alpha (1)
- iCBT (1)
- idiosyncratic drug-induced liver injury (DILI) (1)
- image-guided tissue acquisition (1)
- imaging genetics (1)
- imaging protocol (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitor (ICI) (1)
- immune escape (1)
- immune host defense (1)
- immune infiltration (1)
- immunohistochemistry (1)
- immunological risk (1)
- impulsivity (1)
- incidence (1)
- incontinence (1)
- induction chemotherapy (1)
- induction regimen (1)
- induction therapy (1)
- inertial motion units (1)
- infection (1)
- infection control (1)
- infection precaution (1)
- infections (1)
- infectivity (1)
- inflammasome (1)
- inflammatory bowel disease (1)
- inflammatory reaction (1)
- informal care (1)
- inherited (1)
- inhibitor (1)
- inhibitory control (1)
- injury pattern (1)
- injury prevention (1)
- inosine (1)
- insurance data (1)
- integrate-and-fire (1)
- integrative medicine (1)
- integrative neuromotor training (1)
- intellectual disability (1)
- intensive care admission and mortality (1)
- interim positron emissiontomography (1)
- interleukin-22 (1)
- international transport (1)
- interstitial multicatheter brachytherapy (1)
- intestinal iron loss (1)
- intestinal manipulation (1)
- intracellular (1)
- intracerebral hemorrhage (ICH) (1)
- intracranial hemorrhage (1)
- intranasal administration (1)
- intraoperatively molded (1)
- intravenous iron (1)
- intravenous iron therapy (1)
- intrinsic and innate immune response (1)
- invasive fungal disease (1)
- inverse spacer (1)
- inverse stage migration (1)
- iron deficiency anemia (1)
- iron isomaltoside (1)
- iron-trafficking (1)
- irritable bowel syndrome (1)
- jejunoileal atresia (1)
- joint innervation (1)
- joint load (1)
- juvenile myelomonocytic leukemia (1)
- kidney transplantation (1)
- kinematic analysis (1)
- landrace pigs (1)
- language impairment (1)
- lasso regression (1)
- layer-specificity (1)
- learning and memory (1)
- left atrial appendage occlusion (1)
- legislation (1)
- leisure-time activity (1)
- lenalidomide (1)
- leptin receptor-deficient mouse (1)
- leucocytes (1)
- leukemia (1)
- leukocytes (1)
- leukodystrophy (1)
- life table (1)
- life-expectancy (1)
- lifestyle intervention (1)
- light irradiation (1)
- limitations (1)
- lipids (1)
- lipofilling (1)
- lipofuscin (1)
- live-cell imaging (1)
- live/dead staining (1)
- liver X receptor (1)
- liver damage (1)
- liver metastasis (1)
- liver steatosis (1)
- liver stiffness (1)
- liver volume (1)
- local drug delivery (1)
- local preemptive analgesia (1)
- local recurrence (1)
- local treatment (1)
- location (1)
- locator (1)
- logistic models (1)
- long non-coding RNA (1)
- long term (1)
- long-term outcome (1)
- long-term success (1)
- loss of B-cell phenotype (1)
- loss-of-function (1)
- low molecular weight heparin (1)
- low risk (1)
- low-back-pain (1)
- low-carbohydrate (1)
- low-dose irradiation (1)
- low-glycaemic meal replacement (1)
- lower leg fracture (1)
- lung development (1)
- lung function (1)
- lungs (1)
- lymph node metastases (1)
- mRNA stability (1)
- mRNA1273 (1)
- mTOR (1)
- mTOR inhibitor (1)
- machine-learning (1)
- magnetoencephalography (1)
- male (1)
- malignancy (1)
- mammary carcinoma (1)
- manganese (1)
- marginal fit (1)
- marked lymph node (1)
- mass spectrometry (1)
- mathematical analysis (1)
- mathematical modeling (1)
- mechanotransduction (1)
- medical risk factors (1)
- medulloblastoma (1)
- melanoma (1)
- membrane-less organelles (1)
- membranous urethral stricture (1)
- meningioma (1)
- mental health (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal/stem cells (1)
- mesial temporal lobe epilepsy (1)
- meta-analysis (1)
- metabolic liver disease (1)
- metabolic rewiring (1)
- metabolism (1)
- metabolomics (1)
- metastatic renal cell carcinoma (1)
- mice (1)
- michael acceptor (1)
- microbiome (1)
- microdissection (1)
- microsurgery (1)
- microvesicles (1)
- mild cognitive impairment (1)
- minimally invasive therapy (1)
- minocycline (1)
- mitochondrial disease (1)
- mitochondrial respiration (1)
- mitral regurgitation (1)
- mitral valve surgery (1)
- mold (1)
- molecular marker (1)
- molecular neuroscience (1)
- molecular surveillance (1)
- monitoring (1)
- monoacylglycerol lipase (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- monocytes (1)
- monotherapy (1)
- mood (1)
- morbidity (1)
- motor functions (1)
- motor-control-exercise (1)
- mouse (1)
- mouse models (1)
- mouse tumor model (1)
- mucormycetes (1)
- multi-material 3D printing (1)
- multi-scale models (1)
- multicenter study (1)
- multicentre study (1)
- multidisciplinary-therapy (1)
- multimorbidity (1)
- multiple myeloma (1)
- multisensory integration (1)
- multislice imaging (1)
- multivoxel pattern analysis (1)
- musculoskeletal disorders (1)
- musculoskeletal repair (1)
- musculoskeletal system (1)
- mutation (1)
- mutism (1)
- myeloproliferative neoplasms (MPN) (1)
- myocardial efficiency (1)
- myocardial fibrosis (1)
- myocardial ischaemia (1)
- myocardial power (1)
- nNOS (1)
- nasal swab (1)
- natural selection (1)
- natural sounds (1)
- necroptosis (1)
- neoadjuvant therapy (1)
- neonate (1)
- neovascularization (1)
- nephroureterectomy (1)
- neural correlates (1)
- neural oscillations (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurodevelopmental disorde (1)
- neuroendocrine tumor (1)
- neuroethology (1)
- neurogenic bowel (1)
- neuroimaging (1)
- neurological manifestations (1)
- neurology (1)
- neuropeptide (1)
- neuropeptides (1)
- neuroprotection (1)
- neurotransmitter (1)
- neutralization (1)
- neutralizing antibody (1)
- next-generation sequencing (1)
- nitric oxide (1)
- nitroalkene (1)
- nitroglycerin (1)
- nociception (1)
- nodular lymphocyte-predominant Hodgkin lymphoma (1)
- nomogram (1)
- non-aneurysmal (1)
- non-aneurysmal SAH (1)
- non-coding RNA (1)
- non-contact injuries (1)
- non-perimesencephalic (1)
- non-small cell lung cancer (1)
- nontraumatic atlantoaxial rotatory subluxation (1)
- nucleic acid amplification test (1)
- nucleic acid docking (1)
- nucleic acid lateral flow immunoassay (1)
- nucleolus (1)
- nucleoredoxin (1)
- nutrition - clinical (1)
- nymphs (1)
- obesity (1)
- observational study (1)
- olfaction (1)
- oluble epoxide hydrolase (1)
- oncogenesis (1)
- oncogenic RAS (1)
- oncological exercise therapy (1)
- online intervention (1)
- online research (1)
- online survey (1)
- open field behavior (1)
- open science (1)
- open skill exercise (1)
- operating microscope (1)
- oral health (1)
- oral health burden (1)
- oral progestins (1)
- orale Gestagene (1)
- ordinary differential equations (ODE) (1)
- organ preservation (1)
- organic nitrates (1)
- organotypic culture (1)
- other cause mortality (1)
- otoplasty (1)
- outcomes (1)
- ovarian cancer (1)
- overdenture (1)
- overtreatment (1)
- overweight (1)
- oviposition (1)
- oviposition substrate (1)
- ovitrap (1)
- oxaliplatin (1)
- oxythiamine (1)
- p-eIF2α (1)
- p21Cip1/CDKN1A (1)
- p53 pathway (1)
- pH (1)
- pad-test (1)
- pain intensity (1)
- paired samples (1)
- palliative care (1)
- palliative care services (1)
- pancreatic ductal adenocarcinoma (1)
- pannexin-1 (1)
- paper-based detection (1)
- paracrine signaling (1)
- parent rating (1)
- pathogen (1)
- patient preferences (1)
- patient safety (1)
- patient–doctor relationship (1)
- pediatric solid tumors (1)
- pelvic trauma (1)
- penile cancer (1)
- pentaerythritol tetranitrate (1)
- peptide receptor radionuclide therapy (1)
- perforant path transection (1)
- peri-implant disease (1)
- peri-implant diseases (1)
- peri-implantitis (1)
- peri-implantitis treatment (1)
- periimplantitis (1)
- perimesencephalic (1)
- periodontal diseases (1)
- periodontal treatment (1)
- peripheral blood stem cell collection (1)
- peritoneal macrophages (1)
- peritumoral edema (1)
- peritumoral edema zone (1)
- peroxisome proliferator-activated receptor (1)
- persistent periodontal pockets (1)
- personalized (1)
- phagocytes (1)
- phagocytosis (1)
- pharmacodynamics (1)
- pharmacoepigenetics (1)
- pharmacogenetics (1)
- pharmacological data science (1)
- pharmacological plasticity (1)
- phase IV (1)
- phase separation (1)
- phenoconversion (1)
- pheromone (1)
- phosphoproteomics (1)
- photodynamic therapy (1)
- physical activity (1)
- physiotherapy (1)
- pibrentasvir (1)
- pitch (1)
- plasmid (1)
- platelet hyperactivity (1)
- platelet substitution (1)
- platelet-rich-fibrin (1)
- point-of-care diagnostics (1)
- polo-like kinases (1)
- polyQ (1)
- polycythemia vera (PV) (1)
- polymer infiltrated ceramic network (1)
- polymeric micelle (1)
- polypept(o)ide (1)
- polypharmacy (1)
- polytrauma (1)
- polyunsaturated fatty acid (1)
- portal pressure (1)
- positron-emissions-tomography (1)
- post-transcriptional regulation (1)
- posterior circulation (1)
- postinfectious bronchiolitis obliterans (1)
- postoperative pain (1)
- potassium channel (1)
- preclinical (1)
- prediabetes and type 2 diabetes (1)
- prediction (1)
- predictive (1)
- predictive coding (1)
- predictor (1)
- preeclampsia (1)
- prehabilitation (1)
- prepontine (1)
- preventive strategies (1)
- primary biliary cholangitis (1)
- primary immunodeficiency (1)
- primary myelofibrosis (PMF) (1)
- prion-like (1)
- production (1)
- progestin mono-preparation (1)
- prognostic (1)
- prognostic scores (1)
- progranulin (1)
- promyelocytic leukemia nuclear bodies (1)
- prostate cancer (PCa) (1)
- prostate neoplasm (1)
- proteasome (1)
- protein aggregation (1)
- protein complexes (1)
- protein evolution (1)
- protein folding (1)
- protein phosphorylation (1)
- protein-rich (1)
- protein–protein interaction (1)
- proteoglycan (1)
- proteomics (1)
- proton pumping (1)
- proton-sensing GPCR (1)
- protruding ear (1)
- pseudomonas aeruginosa (1)
- psoriasis (1)
- psychiatric comorbidity (1)
- psychiatric disorders (1)
- psychogenic non-epileptic seizures (1)
- psychosocial factors (1)
- public health (1)
- publication output (1)
- pulsed SILAC (1)
- quantitative MRI (1)
- quantitative RUCAM (1)
- quantitative magnetic resonance imaging (1)
- quiescence (1)
- radiation (1)
- radiation-induced (1)
- radio sensitivity (1)
- radioimmunotherapy (1)
- radiomics (1)
- randomized (1)
- randomized controlled trial (1)
- rare disease (1)
- rare mendelian disorders (1)
- rat calvaria defect (1)
- re-irradiation (1)
- reactive coordination (1)
- reactive oxygen species (1)
- real-world (1)
- recall (1)
- recombinase polymerase amplification (1)
- recovery (1)
- recurrent urinary tract infections (1)
- red cells (1)
- reduced kidney function (1)
- reduction potential (1)
- regenerative therapy (1)
- relapsing–remitting multiple sclerosis (1)
- remodeling (1)
- renal cell carcinoma (1)
- renal dysfunction (1)
- renal failure (1)
- renal tubular epithelial cells (1)
- research database (1)
- research funding (1)
- resectability (1)
- resin nano ceramics (1)
- resistance (1)
- resistance mutation (1)
- resolution (1)
- response (1)
- response inhibition (1)
- resting-state (1)
- reticulocyte hemoglobin equivalent (1)
- retrospective studies (1)
- reverberation (1)
- revision knee arthroplasty (1)
- reward (1)
- reward probabilities (1)
- rheumatoid arthritis (1)
- rifampicin (1)
- risk group (1)
- risk stratification (1)
- room simulation (1)
- safety attitudes questionnaire (1)
- salience network (1)
- saliva (1)
- salvage mastectomy (1)
- salvage radical prostatectomy (1)
- sampling (1)
- sarcoma (1)
- scar (1)
- schizophrenia (1)
- screening questionnaire (1)
- searchlight analysis (1)
- second line therapy (1)
- second-line immunotherapy (1)
- second-line treatment / 2L treatment (1)
- secondary data analysis (1)
- secondary progressive multiple sclerosis (1)
- secreted Ly-6/uPAR-related protein 1 (1)
- seed and soil (1)
- segmental ureteral resection (1)
- self-collected samples (1)
- semiquinone (1)
- sensory loss (1)
- sensory organ development (1)
- serine protease (NS3-4A) (1)
- serum (1)
- severely injured patient (1)
- sex (1)
- sex differences (1)
- sexual arousal (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- shared decision-making (1)
- shear stress (1)
- shikonin (SHI) (1)
- short bowel (1)
- short linear motif (1)
- short-term (1)
- shoulder instability (1)
- shoulder stabilization (1)
- simulation (1)
- simulation training (1)
- sleep deprivation (1)
- sleep disordered breathing (1)
- small bowel (1)
- small ubiquitin-related modifier (1)
- social anxiety (1)
- social communication (1)
- socio-economic influences (1)
- socioeconomic factors (1)
- soft tissue (1)
- soft tissue sarcoma (1)
- solid tumor (1)
- sonoSens (1)
- sorafenib (1)
- sound-induced flash illusion (1)
- spared nerve injury (1)
- speech perception (1)
- sphingolipids (1)
- sphingosine-1-phosphate (1)
- spike mutation (1)
- spike protein (1)
- spina bifida (1)
- spinal bone metastasis (1)
- spinal infection (1)
- spine injury (1)
- spinocerebellar ataxia (1)
- splicing (1)
- split-mouth (1)
- sprouting (1)
- sprouting angiogenesis (1)
- stage (1)
- stage migration (1)
- statin (1)
- statin treatment (1)
- statins (1)
- stoma (1)
- structure-function (1)
- strumpellin (1)
- stuttering (1)
- subarachnoid hemorrhage (1)
- subchondral bone (1)
- subgrouping (1)
- subpopulation (1)
- sulforaphane (1)
- sulfur-oxidizing symbiont (1)
- superparamagnetic iron oxide nanoparticles (1)
- support (1)
- suprachiasmatic nucleus (1)
- surgical complications (1)
- surrogate ELISA (1)
- symbiosis (1)
- symptoms (1)
- synoviocytes (1)
- synovitis (1)
- systematic review (1)
- tDCS (1)
- tVNS (1)
- tachycardia (1)
- target (1)
- targeted axillary dissection (1)
- targeted sequencing (1)
- taste buds (1)
- temporal encephaloceles (1)
- temporal lobe epilepsy (1)
- testosterone (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- tetrahydrocannabinol (1)
- therapy (1)
- therapy response (1)
- thermal ablation (1)
- thrombectomy (1)
- thromboembolism (1)
- thymic selection (1)
- tibial fracture (1)
- tip cell filopodia formation (1)
- tissue reconstruction (1)
- toddler’s fracture (1)
- tolerability (1)
- topical administration (1)
- topographical pattern (1)
- torticollis (1)
- total hip replacement (1)
- toxic milk mice (TX mice) (1)
- toxicity (1)
- traditional Chinese medicine (TCM) (1)
- trafficking (1)
- training (1)
- transduction (1)
- transfer entropy (1)
- transglutaminase (1)
- transient elastography (1)
- transjugular intrahepatic portosystemic shunt (1)
- translational investigation (1)
- translational study (1)
- transmission (1)
- transovarial transmission (1)
- transplant-free survival (1)
- transstadial transmission (1)
- trauma (1)
- traumatic brain injury (1)
- traumatic injury (1)
- treatment outcome (1)
- treatment resistance (1)
- treatment response (1)
- trials registry (1)
- triplex (1)
- trophoblast organoids (1)
- trophoblasts (1)
- trough levels (1)
- tumor immunity (1)
- tumor immunology (1)
- tumor stroma (1)
- tumor-associated macrophages (TAM) (1)
- tunnel technique (1)
- type 2 diabetes (1)
- tyrosine hydroxylase (1)
- tyrosine kinase inhibitor (TKI) (1)
- ubiquitin ligase (1)
- ultra-high risk for psychosis (1)
- unacceptable antigen mismatches (1)
- undifferentiated pleomorphic sarcoma (1)
- unilateral (1)
- unilateral hip osteoarthritis (1)
- upgrading (1)
- upper tract urothelial carcinoma (1)
- ureteroscopy (1)
- urethal stricture (1)
- urethroplasty (1)
- urinary incontinence (1)
- ursodeoxycholic acid (1)
- uveal melanoma (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- vaginal breech (1)
- vaginal hysterectomy (1)
- variants of concern (1)
- vascular biology (1)
- vasodilation (1)
- vector (1)
- venous thrombosis (1)
- ventral otoplasty (1)
- ventral striatum (1)
- ventricular tachycardia (1)
- vergence (1)
- vertigo (1)
- very high-risk (1)
- vestibular function (1)
- viral fitness (1)
- virus (1)
- viruses (1)
- volumetric measurement technology (1)
- von Willebrand disease (1)
- waiting time (1)
- walking (1)
- wearable sensors (1)
- weight reduction (1)
- white matter hyperintensity (1)
- whole-genome sequencing (1)
- work place evaluation (1)
- wound exudate (1)
- wound healing (1)
- wound infection (1)
- wound repair (1)
- yellow flags (1)
- younger (1)
- zinc protoporphyrin (1)
- Übergewicht (1)
- ß-amyloid (1)
- β-HCG (1)
Institute
- Medizin (667)
- Biochemie, Chemie und Pharmazie (8)
- Biowissenschaften (7)
- Psychologie und Sportwissenschaften (6)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (5)
- Georg-Speyer-Haus (4)
- Physik (3)
- Biodiversität und Klima Forschungszentrum (BiK-F) (2)
- Ernst Strüngmann Institut (2)
- Erziehungswissenschaften (2)
Throughout life, macrophages are located in every tissue of the body, where their main roles are to phagocytose cellular debris and recycle aging red blood cells. In the tissue niche, they promote homeostasis through trophic, regulatory, and repair functions by responding to internal and external stimuli. This in turn polarizes macrophages into a broad spectrum of functional activation states, also reflected in their iron-regulated gene profile. The fast adaptation to the environment in which they are located helps to maintain tissue homeostasis under physiological conditions.
Osteoarthritis: novel molecular mechanisms increase our understanding of the disease pathology
(2021)
Although osteoarthritis (OA) is the most common musculoskeletal condition that causes significant health and social problems worldwide, its exact etiology is still unclear. With an aging and increasingly obese population, OA is becoming even more prevalent than in previous decades. Up to 35% of the world’s population over 60 years of age suffers from symptomatic (painful, disabling) OA. The disease poses a tremendous economic burden on the health-care system and society for diagnosis, treatment, sick leave, rehabilitation, and early retirement. Most patients also experience sleep disturbances, reduced capability for exercising, lifting, and walking and are less capable of working, and maintaining an independent lifestyle. For patients, the major problem is disability, resulting from joint tissue destruction and pain. So far, there is no therapy available that effectively arrests structural deterioration of cartilage and bone or is able to successfully reverse any of the existing structural defects. Here, we elucidate novel concepts and hypotheses regarding disease progression and pathology, which are relevant for understanding underlying the molecular mechanisms as a prerequisite for future therapeutic approaches. Emphasis is placed on topographical modeling of the disease, the role of proteases and cytokines in OA, and the impact of the peripheral nervous system and its neuropeptides.
Background and Purpose: Sexual dysfunction (SD) is a frequent side effect associated with radical prostatectomy (RP) for prostate cancer (PCa). Some studies have showed the benefit associated with preoperative sexual rehabilitation (prehabilitation) and Enhanced Recovery After Surgery (ERAS) for RP, but no clear clinical recommendations are available yet. Our aim was to conduct a systematic review on sexual prehabilitation prior to RP for patients with a localized PCa and analyze the impact on postoperative sexual health compared with the standard post-operative care.
Methods: We performed a systematic review of the literature following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) recommendations.
Results: Four randomized control trials and one retrospective comparative study were included in the analyses. Three of the five studies showed an improved EF recovery post-RP in the prehabilitation group compared to the standard of care represented by: higher International Index of Erectile Function 5 score (IIEF5) or IIEF score (p < 0.0001) and a higher percentage of patients reporting return of EF based on the Sexual Encounter Profile (SEP) (56 vs. 24%, p = 0.007). Self-confidence, therapeutic alliance, and adherence to treatment were stronger for patients with preoperative consultations (p < 0.05) and EF recovery was better in cases of a higher number of follow-up visits (OR 4–5 visits vs. 1:12.19, p = 0.002).
Discussion: Despite heterogenous methods and high risks of bias in this systematic review, starting sexual rehabilitation prior to surgery seems to ensure better EF recovery. This prehabilitation should include information of both the patient and his or her partner, with a closer follow up and the use of a multimodal treatment approach that still remains to be defined and validated (oral medication, vacuum devices, pelvic floor muscle training, etc.).
Trehalose, a sugar from fungi, mimics starvation due to a block of glucose transport and induces Transcription Factor EB- mediated autophagy, likely supported by the upregulation of progranulin. The pro-autophagy effects help to remove pathological proteins and thereby prevent neurodegenerative diseases such as Alzheimer’s disease. Enhancing autophagy also contributes to the resolution of neuropathic pain in mice. Therefore, we here assessed the effects of continuous trehalose administration via drinking water using the mouse Spared Nerve Injury model of neuropathic pain. Trehalose had no effect on drinking, feeding, voluntary wheel running, motor coordination, locomotion, and open field, elevated plus maze, and Barnes Maze behavior, showing that it was well tolerated. However, trehalose reduced nerve injury-evoked nociceptive mechanical and thermal hypersensitivity as compared to vehicle. Trehalose had no effect on calcium currents in primary somatosensory neurons, pointing to central mechanisms of the antinociceptive effects. In IntelliCages, trehalose-treated mice showed reduced activity, in particular, a low frequency of nosepokes, which was associated with a reduced proportion of correct trials and flat learning curves in place preference learning tasks. Mice failed to switch corner preferences and stuck to spontaneously preferred corners. The behavior in IntelliCages is suggestive of sedative effects as a 'side effect' of a continuous protracted trehalose treatment, leading to impairment of learning flexibility. Hence, trehalose diet supplements might reduce chronic pain but likely at the expense of alertness.
In humans, alterations of circadian rhythms and autophagy are linked to metabolic, cardiovascular and neurological dysfunction. Autophagy constitutes a specific form of cell recycling in many eukaryotic cells. Aging is the principal risk factor for the development of neurodegenerative diseases. Thus, we assume that both the circadian clock and autophagy are indispensable to counteract aging. We have previously shown that the hippocampus of Per1−/−-mice exhibits a reduced autophagy and higher neuronal susceptibility to ischemic insults compared to wild type (WT). Therefore, we chose to study the link between aging and loss of clock gene Per1−/−-mice. Young and aged C3H- and Per1−/−-mice were used as models to analyze the hippocampal distribution of Aβ42, lipofuscin, presenilin, microglia, synaptophysin and doublecortin. We detected several changes in the hippocampus of aged Per1−/−-mice compared to their wild type littermates. Our results show significant alterations of microglia morphology, an increase in Aβ42 deposition, overexpression of presenilin, decrease in synaptophysin levels and massive accumulation of lipofuscin in the hippocampus of 24-month-old Per1−/−-mice, without alteration of adult neurogenesis. We suggest that the marked lipofuscin accumulation, Aβ42 deposition, and overexpression of presenilin-2 observed in our experiments may be some of the consequences of the slowed autophagy in the hippocampus of aged Per1−/−-mice. This may lead during aging to excessive accumulation of misfolded proteins which may, consequently, result in higher neuronal vulnerability.
The group of proton-sensing G-protein coupled receptors (GPCRs) consists of the four receptors GPR4, TDAG8 (GPR65), OGR1 (GPR68), and G2A (GPR132). These receptors are cellular sensors of acidification, a property that has been attributed to the presence of crucial histidine residues. However, the pH detection varies considerably among the group of proton-sensing GPCRs and ranges from pH of 5.5 to 7.8. While the proton-sensing GPCRs were initially considered to detect acidic cellular environments in the context of inflammation, recent observations have expanded our knowledge about their physiological and pathophysiological functions and many additional individual and unique features have been discovered that suggest a more differentiated role of these receptors in health and disease. It is known that all four receptors contribute to different aspects of tumor biology, cardiovascular physiology, and asthma. However, apart from their overlapping functions, they seem to have individual properties, and recent publications identify potential roles of individual GPCRs in mechanosensation, intestinal inflammation, oncoimmunological interactions, hematopoiesis, as well as inflammatory and neuropathic pain. Here, we put together the knowledge about the biological functions and structural features of the four proton-sensing GPCRs and discuss the biological role of each of the four receptors individually. We explore all currently known pharmacological modulators of the four receptors and highlight potential use. Finally, we point out knowledge gaps in the biological and pharmacological context of proton-sensing GPCRs that should be addressed by future studies.
Exogenous adenosine and its metabolite inosine exert anti-inflammatory effects in synoviocytes of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. We analyzed whether these cells are able to synthesize adenosine/inosine and which adenosine receptors (ARs) contribute to anti-inflammatory effects. The functionality of synthesizing enzymes and ARs was tested using agonists/antagonists. Both OA and RA cells expressed CD39 (converts ATP to AMP), CD73 (converts AMP to adenosine), ADA (converts adenosine to inosine), ENT1/2 (adenosine transporters), all AR subtypes (A1, A2A, A2B and A3) and synthesized predominantly adenosine. The CD73 inhibitor AMPCP significantly increased IL-6 and decreased IL-10 in both cell types, while TNF only increased in RA cells. The ADA inhibitor DAA significantly reduced IL-6 and induced IL-10 in both OA and RA cells. The A2AAR agonist CGS 21680 significantly inhibited IL-6 and induced TNF and IL-10 only in RA, while the A2BAR agonist BAY 60-6583 had the same effect in both OA and RA. Taken together, OA and RA synoviocytes express the complete enzymatic machinery to synthesize adenosine/inosine; however, mainly adenosine is responsible for the anti- (IL-6 and IL-10) or pro-inflammatory (TNF) effects mediated by A2A- and A2BAR. Stimulating CD39/CD73 with simultaneous ADA blockage in addition to TNF inhibition might represent a promising therapeutic strategy.
The purpose of the study was to investigate the bacterial viability of the initial biofilm on the surface of experimental modified dental resin composites. Twenty-five healthy individuals with good oral hygiene were included in this study. In a split-mouth design, they received acrylic splints with five experimental composite resin specimens. Four of them were modified with either a novel polymeric hollow-bead delivery system or methacrylated polymerizable Irgasan (Antibacterial B), while one specimen served as an unmodified control (ST). A delivery system based on Poly-Pore® was loaded with one of the active agents: Tego® Protect 5000 (Antiadhesive A), Dimethicone (Antiadhesive B), or Irgasan (Antibacterial A). All study subjects refrained from toothbrushing during the study period. Specimens were detached from the splints after 8 h and given a live/dead staining before fluorescence microscopy. A Friedman test and a post hoc Nemenyi test were applied with a significance level at p < 0.05. In summary, all materials but Antibacterial B showed a significant antibacterial effect compared to ST. The results suggested the role of the materials’ chemistry in the dominance of cell adhesion. In conclusion, dental resin composites with Poly-Pore-loaded active agents showed antibacterial effectiveness in situ.
Purpose This study aims to define the extent of additional surgical procedures after abdominal wall closure (AWC) in patients with gastroschisis (GS) and omphalocele (OC) with special focus on gastrointestinal related operations. Methods A retrospective chart review was performed including all operations in GS and OC patients in the first year after AWC (2010–2019). The risk for surgery was calculated using the one-year cumulative incidence (CI). Results 33 GS patients (18 simple GS, 15 complex) and 24 OC patients (12 without (= OCL), 12 OC patients with liver pro-trusion (= OCL +)) were eligible for analysis. 43 secondary operations (23 in GS, 20 in OC patients) occurred after a median time of 84 days (16–824) in GS and 114.5 days (12–4368) in OC. Patients with complex versus simple GS had a significantly higher risk of undergoing a secondary operation (one-year CI 64.3% vs. 24.4%; p = 0.05). 86.5% of surgical procedures in complex GS and 36.3% in OCL + were related to gastrointestinal complications. Complex GS had a significantly higher risk for GI-related surgery than simple GS. Bowel obstruction was a risk factor for surgery in complex GS (one-year CI 35.7%). Conclusion Complex GS and OCL + patients had the highest risk of undergoing secondary operations, especially those with gastrointestinal complications
Background: Excessive alcohol intake is associated with adverse immune response-related effects, however, acute and chronic abuse differently modulate monocyte activation. In this study, we have evaluated the phenotypic and functional changes of monocytes in acutely intoxicated healthy volunteers (HV).
Methods: Twenty-two HV consumed individually adjusted amounts of alcoholic beverages until reaching a blood alcohol level of 1‰ after 4h (T4). Peripheral blood was withdrawn before and 2h (T2), 4h (T4), 6h (T6), 24h (T24), and 48h (T48) after starting the experiment and stained for CD14, CD16 and TLR4. CD14brightCD16-, CD14brightCD16+ and CD14dimCD16+ monocyte subsets and their TLR4 expression were analyzed by flow cytometry. Inflammasome activation via caspase-1 in CD14+ monocytes was measured upon an ex vivo in vitro LPS stimulation. Systemic IL-1β and adhesion capacity of isolated CD14+ monocytes upon LPS stimulation were evaluated.
Results: The percentage of CD14+ monocyte did not change following alcohol intoxication, whereas CD14brightCD16- monocyte subset significantly increased at T2 and T24, CD14brightCD16+ at T2, T4 and T6 and CD14dimCD16+ at T4 and T6. The relative fraction of TLR4 expressing CD14+ monocytes as well as the density of TLR4 surface presentation increased at T2 and decreased at T48 significantly. TLR4+CD14+ monocytes were significantly enhanced in all subsets at T2. TLR4 expression significantly decreased in CD14brightCD16- at T48, in CD14brightCD16+ at T24 and T48, increased in CD14dimCD16+ at T2. IL-1β release upon LPS stimulation decreased at T48, correlating with TLR4 receptor expression. Alcohol downregulated inflammasome activation following ex vivo in vitro stimulation with LPS between T2 and T48 vs. T0. The adhesion capacity of CD14+ monocytes decreased from T2 with significance at T4, T6 and T48. Following LPS administration, a significant reduction of adhesion was observed at T4 and T6.
Conclusions: Alcohol intoxication immediately redistributes monocyte subsets toward the pro-inflammatory phenotype with their subsequent differentiation into the anti-inflammatory phenotype. This is paralleled by a significant functional depression, suggesting an alcohol-induced time-dependent hyporesponsiveness of monocytes to pathogenic triggers.
Kinase fusions are considered oncogenic drivers in numerous types of cancer. In lung adenocarcinoma 5–10% of patients harbor kinase fusions. The most frequently detected kinase fusion involves the Anaplastic Lymphoma Kinase (ALK) and Echinoderm Microtubule-associated protein-Like 4 (EML4). In addition, oncogenic kinase fusions involving the tyrosine kinases RET and ROS1 are found in smaller subsets of patients. In this study, we employed quantitative mass spectrometry-based phosphoproteomics to define the cellular tyrosine phosphorylation patterns induced by different oncogenic kinase fusions identified in patients with lung adenocarcinoma. We show that exogenous expression of the kinase fusions in HEK 293T cells leads to widespread tyrosine phosphorylation. Direct comparison of different kinase fusions demonstrates that the kinase part and not the fusion partner primarily defines the phosphorylation pattern. The tyrosine phosphorylation patterns differed between ALK, ROS1, and RET fusions, suggesting that oncogenic signaling induced by these kinases involves the modulation of different cellular processes.
Traditional ergonomic risk assessment tools such as the Rapid Upper Limb Assessment (RULA) are often not sensitive enough to evaluate well-optimized work routines. An implementation of kinematic data captured by inertial sensors is applied to compare two work routines in dentistry. The surgical dental treatment was performed in two different conditions, which were recorded by means of inertial sensors (Xsens MVN Link). For this purpose, 15 (12 males/3 females) oral and maxillofacial surgeons took part in the study. Data were post processed with costume written MATLAB® routines, including a full implementation of RULA (slightly adjusted to dentistry). For an in-depth comparison, five newly introduced levels of complexity of the RULA analysis were applied, i.e., from lowest complexity to highest: (1) RULA score, (2) relative RULA score distribution, (3) RULA steps score, (4) relative RULA steps score occurrence, and (5) relative angle distribution. With increasing complexity, the number of variables times (the number of resolvable units per variable) increased. In our example, only significant differences between the treatment concepts were observed at levels that are more complex: the relative RULA step score occurrence and the relative angle distribution (level 4 + 5). With the presented approach, an objective and detailed ergonomic analysis is possible. The data-driven approach adds significant additional context to the RULA score evaluation. The presented method captures data, evaluates the full task cycle, and allows different levels of analysis. These points are a clear benefit to a standard, manual assessment of one main body position during a working task.
Sulforaphane (SFN) is a natural glucosinolate found in cruciferous vegetables that acts as a chemopreventive agent, but its mechanism of action is not clear. Due to antioxidative mechanisms being thought central in preventing cancer progression, SFN could play a role in oxidative processes. Since redox imbalance with increased levels of reactive oxygen species (ROS) is involved in the initiation and progression of bladder cancer, this mechanism might be involved when chemoresistance occurs. This review summarizes current understanding regarding the influence of SFN on ROS and ROS-related pathways and appraises a possible role of SFN in bladder cancer treatment.
Background and Aims. Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. Methods. A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. Results. A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3–9.7), 4.1 months (95% CI: 3.6–4.7) and 5.0 months (95% CI: 2.9–7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0–18.1), 8.4 months (95% CI: 6.0–10.8) and 10.5 months (95% CI: 7.5–13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. Conclusions. Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.
Adapting movements rapidly to unanticipated external stimuli is paramount for athletic performance and to prevent injuries. We investigated the effects of a 4-week open-skill choice-reaction training intervention on unanticipated jump-landings. Physically active adults (n = 37; mean age 27, standard deviation 2.7 years, 16 females, 21 males) were randomly allocated to one of two interventions or a control group (CG). Participants in the two intervention groups performed a 4-week visuomotor open skill choice reaction training, one for the upper and one for the lower extremities. Before and after the intervention, two different types of countermovement jumps with landings in split stance position were performed. In the (1) pre-planned condition, we informed the participants regarding the landing position (left or right foot in front position) before the jump. In the (2) unanticipated condition, this information was displayed after take-off (350–600 ms reaction time before landing). Outcomes were landing stability [peak vertical ground reaction force (pGRF) and time to stabilization (TTS)], and landing-related decision-making quality (measured by the number of landing errors). To measure extremity-specific effects, we documented the number of correct hits during the trained drills. A two-factorial (four repeated measures: two conditions, two time factors; three groups) ANCOVA was carried out; conditions = unanticipated versus pre-planned condition, time factors = pre versus post measurement, grouping variable = intervention allocation, co-variates = jumping time and self-report arousal. The training improved performance over the intervention period (upper extremity group: mean of correct choice reaction hits during 5 s drill: +3.0 hits, 95% confidence interval: 2.2–3.9 hits; lower extremity group: +1.6 hits, 0.6–2.6 hits). For pGRF (F = 8.4, p < 0.001) and landing errors (F = 17.1, p < 0.001) repeated measures effect occurred. Significantly more landing errors occurred within the unanticipated condition for all groups and measurement days. The effect in pGRF is mostly impacted by between-condition differences in the CG. No between-group or interaction effect was seen for these outcomes: pGRF (F = 0.4, p = 0.9; F = 2.3, p = 0.1) landing errors (F = 0.5, p = 0.6; F = 2.3, p = 0.1). TTS displayed a repeated measures (F = 4.9, p < 0.001, worse values under the unanticipated condition, improvement over time) and an interaction effect (F = 2.4, p = 0.03). Healthy adults can improve their choice reaction task performance by training. As almost no transfer to unanticipated landing successfulness or movement quality occurred, the effect seems to be task-specific. Lower-extremity reactions to unanticipated stimuli may be improved by more specific training regimens.
Magnetic resonance-guided laser interstitial laser therapy (MRgLITT) and radiofrequency ablation (RFA) represent two minimally invasive methods for the treatment of drug-refractory mesial temporal lobe epilepsy (mTLE). We performed a systematic review and a meta-analysis to compare outcomes and complications between MRgLITT, RFA, and conventional surgical approaches to the temporal lobe (i.e., anterior temporal lobe resection [ATL] or selective amygdalohippocampectomy [sAHE]). Forty-three studies (13 MRgLITT, 6 RFA, and 24 surgery studies) involved 554, 123, 1504, and 1326 patients treated by MRgLITT, RFA, ATL, or sAHE, respectively. Engel Class I (Engel-I) outcomes were achieved after MRgLITT in 57% (315/554, range = 33.3%–67.4%), RFA in 44% (54/123, range = 0%–67.2%), ATL in 69% (1032/1504, range = 40%–92.9%), and sAHE in 66% (887/1326, range = 21.4%–93.3%). Meta-analysis revealed no significant difference in seizure outcome between MRgLITT and RFA (Q = 2.74, p = .098), whereas ATL and sAHE were both superior to MRgLITT (ATL: Q = 8.92, p = .002; sAHE: Q = 4.33, p = .037) and RFA (ATL: Q = 6.42, p = .0113; sAHE: Q = 5.04, p = .0247), with better outcome in patients at follow-up of 60 months or more. Mesial hippocampal sclerosis (mTLE + hippocampal sclerosis) was associated with significantly better outcome after MRgLITT (Engel-I outcome in 64%; Q = 8.55, p = .0035). The rate of major complications was 3.8% for MRgLITT, 3.7% for RFA, 10.9% for ATL, and 7.4% for sAHE; the differences did not show statistical significance. Neuropsychological deficits occurred after all procedures, with left-sided surgeries having a higher rate of verbal memory impairment. Lateral functions such as naming or object recognition may be more preserved in MRgLITT. Thermal therapies are effective techniques but show a significantly lower rate of Engel-I outcome in comparison to ATL and sAHE. Between MRgLITT and RFA there were no significant differences in Engel-I outcome, whereby the success of treatment seems to depend on the approach used (e.g., occipital approach). MRgLITT shows a similar rate of complications compared to RFA, whereas patients undergoing MRgLITT may experience fewer major complications compared to ATL or sAHE and might have a more beneficial neuropsychological outcome.
Background: We hypothesized that lymph node dissection (LND) at salvage radical prostatectomy may be associated with lower cancer-specific mortality (CSM) and we tested this hypothesis.
Methods: We relied on surveillance, epidemiology, and end results (2004–2016) to identify all salvage radical prostatectomy patients. Categorical, as well as univariate and multivariate Cox regression models tested the effect of LND (LND performed vs. not), as well as at its extent (log-transformed lymph node count) on CSM.
Results: Of 427 salvage radical prostatectomy patients, 120 (28.1%) underwent LND with a median lymph node count of 6 (interquartile range [IQR], 3–11). According to LND status, no significant or clinically meaningful differences were recorded in PSA at diagnosis, stage and biopsy Gleason score at diagnosis, except for age at prostate cancer diagnosis (LND performed 63 vs. 68 years LND not performed, p < .001). LND status (performed) was an independent predictor of lower CSM (hazard ratio [HR] 0.47; p = .03). Similarly, lymph node count (log transformed) also independently predicted lower CSM (HR: 0.60; p = .01). After the 7th removed lymph node, the effect of CSM became marginal. The effect of N-stage on CSM could not be tested due to insufficient number of observations.
Conclusions: Salvage radical prostatectomy is rarely performed and LND at salvage radical prostatectomy is performed in a minority of patients. However, LND at salvage radical prostatectomy is associated with lower CSM. Moreover, LND extent also exerts a protective effect on CSM. These observations should be considered in salvage radical prostatectomy candidates.
Purpose: Dexamethasone (Dex) is the most common corticosteroid to treat edema in glioblastoma (GBM) patients. Recent studies identified the addition of Dex to radiation therapy (RT) to be associated with poor survival. Independently, Tumor Treating Fields (TTFields) provides a novel anti-cancer modality for patients with primary and recurrent GBM. Whether Dex influences the efficacy of TTFields, however, remains elusive. Methods: Human GBM cell lines MZ54 and U251 were treated with RT or TTFields in combination with Dex and the effects on cell counts and cell death were determined via flow cytometry. We further performed a retrospective analysis of GBM patients with TTFields treatment +/- concomitant Dex and analysed its impact on progression-free (PFS) and overall survival (OS). Results: The addition of Dex significantly reduced the efficacy of RT in U251, but not in MZ54 cells. TTFields (200 kHz/250 kHz) induced massive cell death in both cell lines. Concomitant treatment of TTFields and Dex did not reduce the overall efficacy of TTFields. Further, in our retrospective clinical analysis, we found that the addition of Dex to TTFields therapy did not influence PFS nor OS. Conclusion: Our translational investigation indicates that the efficacy of TTFields therapy in patients with GBM and GBM cell lines is not affected by the addition of Dex.
Objectives: To evaluate peri-implant tissue dimensions following nonsurgical (NS) and surgical therapy (S) employing different decontamination protocols of advanced ligature-induced peri-implantitis in dogs.
Material & Methods: Peri-implantitis defects (n = 5 dogs, n = 30 implants) were randomly and equally allocated in a split-mouth design to NS or S treatment using either an Er:YAG laser (ERL), an ultrasonic device (VUS), or plastic curettes + local application of metronidazole gel (PCM), respectively. Horizontal bone thickness (hBT) and soft tissue thickness (hMT) were measured at different reference points: (v0) at the marginal portion of the peri-implant mucosa (PM); (v1) at 50% of the distance from PM to bone crest (BC); (v2) at the BC; (v3) at the most coronal extension of the bone-to-implant contact. Vertical peri-implant tissue height was calculated from PM to BC.
Results: All of the treatment groups showed a gradual hMT increase from v0 to the v2 reference point, followed by a reduction from v2 to the v3 region. The S-VUS subgroup tended to be associated with higher hMT values at the v0 region than the NS-VUS subgroup (0.44 mm versus 0.31 mm). PM-BC distance varied from 2.22 to 2.83 mm in the NS group, and from 2.07 to 2.38 in the S group.
Conclusion: Vertical and horizontal peri-implant tissue dimensions were similar in different treatment groups.
Background: Facial skin cancer lesions in close proximity to critical organs require further development of radiotherapeutic techniques for highly conformal treatment, especially when treating elderly frail patients. We report on our treatment technique and first clinical experience for patients with perinasal/periorbital skin cancer treated with individualized epithetic mold high-dose-rate brachytherapy (BRT).
Methods: From January 2019, patients with complex shaped or unfavorably located skin cancer not eligible for surgery or external beam radiotherapy (RT) were screened for mold-based BRT. Six patients were identified. Toxicity and clinical response were documented during therapy and posttreatment follow-up.
Results: Median patient age was 80 years (74–92 years). Median prescription dose was 42 Gy (range, 33–44 Gy) delivered in once-daily fractions of 3 or 4 Gy. Two patients had treatment interruptions caused by acute conjunctivitis grade 2 and a nontreatment-related cardiac event, respectively. At a median follow-up of 335 days (96–628 days), no ≥ grade 2 late toxicity was documented with all patients showing complete clinical response.
Conclusions: High-dose-rate BRT with individualized epithetic molds for perinasal/periorbital skin cancer is a well-tolerated and safe treatment option for patients not eligible for primary surgery or definitive external beam RT because of comorbidities or tumor location.
Objective: This study was undertaken to identify temporal encephaloceles (TEs) and examine their characteristics in patients with temporal lobe epilepsy (TLE) and ex- tratemporal lobe epilepsy (ETLE), as well as in asymptomatic cases.
Methods: Four hundred fifty-eight magnetic resonance imaging scans were exam- ined retrospectively to identify TE in 157 patients with TLE, 150 patients with ETLE, and 151 healthy controls (HCs).
Results: At least one TE was identified in 9.6% of the TLE patients (n = 15, 95% confidence interval [CI] = 5.3%–15.3%), in 3.3% of patients with ETLE (n = 5, 95% CI = 1.1%–7.6%), and in 2.0% of the HCs (n = 3, 95% CI = .4%–5.7%), indicating a significantly higher frequency in patients with TLE compared to ETLE and HC sub- jects (p = .027, p = .005). Examining the characteristics of TEs in both asymptomatic and epilepsy patients, we found that TEs with a diameter of less than 6.25 mm were more likely to be asymptomatic, with a sensitivity of 91.7% and a specificity of 73.3% (area under the curve = .867, 95% CI = .723–1.00, p = .001).
Significance: Temporal encephaloceles may occur without presenting any clinical symp- toms. Patients with TLE show a higher frequency of TEs compared to the ETLE and HC groups. According to our study, TE size could be used to suggest potential epileptogenicity.
Alkylglycerol monooxygenase (AGMO) is a tetrahydrobiopterin (BH4)-dependent enzyme with major expression in the liver and white adipose tissue that cleaves alkyl ether glycerolipids. The present study describes the disclosure and biological characterization of a candidate compound (Cp6), which inhibits AGMO with an IC50 of 30–100 µM and 5–20-fold preference of AGMO relative to other BH4-dependent enzymes, i.e., phenylalanine-hydroxylase and nitric oxide synthase. The viability and metabolic activity of mouse 3T3-L1 fibroblasts, HepG2 human hepatocytes and mouse RAW264.7 macrophages were not affected up to 10-fold of the IC50. However, Cp6 reversibly inhibited the differentiation of 3T3-L1 cells towards adipocytes, in which AGMO expression was upregulated upon differentiation. Cp6 reduced the accumulation of lipid droplets in adipocytes upon differentiation and in HepG2 cells exposed to free fatty acids. Cp6 also inhibited IL-4-driven differentiation of RAW264.7 macrophages towards M2-like macrophages, which serve as adipocyte progenitors in adipose tissue. Collectively, the data suggest that pharmacologic AGMO inhibition may affect lipid storage.
Simple Summary:
CDK9, in combination with Cyclin T1, is one of the major regulators of RNA Polymerase II mediated productive transcription of critical genes in any cell. The activity of CDK9 is significantly up-regulated in a wide variety of cancer entities, to aid in the overexpression of genes responsible for the regulation of functions, which are beneficial to the cancer cells, like proliferation, survival, cell cycle regulation, DNA damage repair and metastasis. Enhanced CDK9 activity, therefore, leads to poorer prognosis in many cancer types, offering the rationale to target it using small-molecule inhibitors. Several, increasingly specific inhibitors, have been developed, some of which are presently in clinical trials. Other approaches being tested involve combining inhibitors against CDK9 activity with those against CDK9’s upstream regulators like BRD4, SEC and HSP90; or downstream effectors like cMYC and MCL-1. The inhibition of CDK9’s activity holds the potential to be a highly effective anti-cancer therapeutic.
Abstract:
Cyclin Dependent Kinase 9 (CDK9) is one of the most important transcription regulatory members of the CDK family. In conjunction with its main cyclin partner—Cyclin T1, it forms the Positive Transcription Elongation Factor b (P-TEFb) whose primary function in eukaryotic cells is to mediate the positive transcription elongation of nascent mRNA strands, by phosphorylating the S2 residues of the YSPTSPS tandem repeats at the C-terminus domain (CTD) of RNA Polymerase II (RNAP II). To aid in this process, P-TEFb also simultaneously phosphorylates and inactivates a number of negative transcription regulators like 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) Sensitivity-Inducing Factor (DSIF) and Negative Elongation Factor (NELF). Significantly enhanced activity of CDK9 is observed in multiple cancer types, which is universally associated with significantly shortened Overall Survival (OS) of the patients. In these cancer types, CDK9 regulates a plethora of cellular functions including proliferation, survival, cell cycle regulation, DNA damage repair and metastasis. Due to the extremely critical role of CDK9 in cancer cells, inhibiting its functions has been the subject of intense research, resulting the development of multiple, increasingly specific small-molecule inhibitors, some of which are presently in clinical trials. The search for newer generation CDK9 inhibitors with higher specificity and lower potential toxicities and suitable combination therapies continues. In fact, the Phase I clinical trials of the latest, highly specific CDK9 inhibitor BAY1251152, against different solid tumors have shown good anti-tumor and on-target activities and pharmacokinetics, combined with manageable safety profile while the phase I and II clinical trials of another inhibitor AT-7519 have been undertaken or are undergoing. To enhance the effectiveness and target diversity and reduce potential drug-resistance, the future of CDK9 inhibition would likely involve combining CDK9 inhibitors with inhibitors like those against BRD4, SEC, MYC, MCL-1 and HSP90.
Popular media now often present 3D printing as a widely employed technology for the production of dental prostheses. This article aims to show, based on factual information, to what extent 3D printing can be used in dental laboratories and dental practices at present. It attempts to present a rational evaluation of todays´ applications of 3D printing technology in the context of dental restorations. In addition, the article discusses future perspectives and examines the ongoing viability of traditional dental laboratory services and manufacturing processes. It also shows which expertise is needed for the digital additive manufacturing of dental restorations.
Survival following relapse in children with Acute Myeloid leukemia: a report from AML-BFM and COG
(2021)
Simple Summary: Acute myeloid leukemia in children remains a difficult disease to cure despite intensive therapies that push the limits of tolerability. Though the intent of initial therapy should be the prevention of relapse, about 30% of all patients experience a relapse. Hence, relapse therapy remains critically important for survival. This retrospective analysis of two large international study groups (COG and BFM) was undertaken to describe the current survival, response rates and clinical features that predict outcomes. We demonstrate that children with relapsed AML may be cured with cytotoxic therapy followed by HSCT. High-risk features at initial diagnosis and early relapse remain prognostic for post-relapse survival. Current response criteria are not aligned with the standards of care for children, nor are the count recovery thresholds meaningful for prognosis in children with relapsed AML. Our data provide a new baseline for future treatment planning and will allow an updated stratification in upcoming studies.
Abstract: Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 ± 4% (BFM) and 35 ± 2% (COG). Initial high-risk features (BFM 32 ± 6%, COG 26 ± 4%) and short time to relapse (BFM 29 ± 4%, COG 25 ± 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 ± 7% vs. 63 ± 10%, p = 0.39). Among 90 patients alive at last follow-up, 87 had received a post-relapse hematopoietic stem cell transplant (HSCT). OS for patients with post-relapse HSCT was 54 ± 4%. In conclusion, initial high-risk features and early relapse remain prognostic. Response assessment with full hematopoietic recovery following initial relapse therapy does not predict survival. These data indicate the need for post-relapse risk stratification in future studies of relapse therapies.
Polo-like kinases (PLKs) belong to a five-membered family of highly conserved serine/threonine kinases (PLK1-5) that play differentiated and essential roles as key mitotic kinases and cell cycle regulators and with this in proliferation and cellular growth. Besides, evidence is accumulating for complex and vital non-mitotic functions of PLKs. Dysregulation of PLKs is widely associated with tumorigenesis and by this, PLKs have gained increasing significance as attractive targets in cancer with diagnostic, prognostic and therapeutic potential. PLK1 has proved to have strong clinical relevance as it was found to be over-expressed in different cancer types and linked to poor patient prognosis. Targeting the diverse functions of PLKs (tumor suppressor, oncogenic) are currently at the center of numerous investigations in particular with the inhibition of PLK1 and PLK4, respectively in multiple cancer trials. Functions of PLKs and the effects of their inhibition have been extensively studied in cancer cell culture models but information is rare on how these drugs affect benign tissues and organs. As a step further towards clinical application as cancer targets, mouse models therefore play a central role. Modelling PLK function in animal models, e.g., by gene disruption or by treatment with small molecule PLK inhibitors offers promising possibilities to unveil the biological significance of PLKs in cancer maintenance and progression and give important information on PLKs’ applicability as cancer targets. In this review we aim at summarizing the approaches of modelling PLK function in mice so far with a special glimpse on the significance of PLKs in ovarian cancer and of orthotopic cancer models used in this fatal malignancy.
Simple Summary: Penile cancer is a rare but aggressive malignancy characterized by rapid tumor growth as well as prompt metastasis in groin lymphatics. While localized diseases can be successfully cured by surgery in most cases, no truly effective treatment options have been established for metastatic diseases as of yet. In the current investigation, we assessed the value of selected members of the PI3K/mTOR/AKT pathway to serve as tumor markers or therapeutic targets for this disease. Higher expression of AKT was significantly more prevalent in high-grade tumors and independently predictive of the worse survival parameters, while increased expression of pmTOR was associated with an inferior prognosis as well. Treatment with the pan-AKT inhibitor capivasertib in PeCa cell lines induced significant reduction of cell viability and movement capacity. These findings might aid in the understanding of the molecular tumor background as well as development of novel treatment options for advanced penile cancer.
Abstract: The PI3K/mTOR/AKT pathway might represent an intriguing option for treatment of penile cancer (PeCa). We aimed to assess whether members of this pathway might serve as biomarkers and targets for systemic therapy. Tissue of primary cancer from treatment-naïve PeCa patients was used for tissue microarray analysis. Immunohistochemical staining was performed with antibodies against AKT, pAKT, mTOR, pmTOR, pS6, pPRAS, p4EBP1, S6K1 and pp70S6K. Protein expression was correlated with clinicopathological characteristics as well as overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS) and metastasis-free survival (MFS). AKT inhibition was tested in two primarily established, treatment-naïve PeCa cell lines by treatment with capivasertib and analysis of cell viability and chemotaxis. A total of 76 patients surgically treated for invasive PeCa were included. Higher expression of AKT was significantly more prevalent in high-grade tumors and predictive of DSS and OS in the Kaplan–Meier analysis, and an independent predictor of worse OS and DSS in the multivariate regression analysis. Treatment with pan-AKT inhibitor capivasertib in PeCa cell lines induced a significant downregulation of both total AKT and pAKT as well as decreased cell viability and chemotaxis. Selected protein candidates of the mTOR/AKT signaling pathway demonstrate association with histological and survival parameters of PeCa patients, whereas AKT appears to be the most promising one.
Simple Summary: The introduction of BRAF/MEK-directed targeted therapy (TT) has significantly improved the management of patients with advanced BRAF-V600-mutant melanoma. Although resistance occurs, there is a subgroup of patients showing a complete response (CR) to TT and who maintain durable disease control. For these patients with durable CR, it is not clear whether it is safe to cease therapy. In this retrospective, multicenter study we have analyzed 37 patients who received TT and achieved a CR upon treatment. We identified 15 patients with a durable CR to TT. Overall, patients who discontinued TT (n = 26) were at higher risk of tumor progression compared to patients receiving ongoing TT. Sustained CR was however not restricted to patients with ongoing TT (n = 11) but was also found in patients who ceased TT (n = 4). Finally, our analysis indicated which patients with an initial CR might be most likely to maintain durable CR upon discontinuation of TT.
Abstract: The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. Of 461 patients who received BRAF/MEK-directed TT 37 achieved a CR. TP after initial CR was observed in 22 patients (60%) mainly affecting patients who discontinued TT (n = 22/26), whereas all patients with ongoing TT (n = 11) maintained their CR. Accordingly, patients who discontinued TT had a higher risk of TP compared to patients with ongoing treatment (p < 0.001). However, our data also show that patients who received TT for more than 16 months and who discontinued TT for other reasons than TP or toxicity did not have a shorter PFS compared to patients with ongoing treatment. Response rates to second-line treatment being initiated in 21 patients, varied between 27% for immune-checkpoint inhibitors (ICI) and 60% for BRAFi/MEKi rechallenge. In summary, we identified a considerable number of patients who achieved a CR upon BRAF/MEK-directed TT in this contemporary real-world cohort of patients with BRAF-V600-mutant melanoma. Sustained PFS was not restricted to ongoing TT but was also found in patients who discontinued TT.
Simple Summary: Early and accurate diagnosis of breast cancer that has spread to other organs and tissues is crucial, as therapeutic decisions and outcome expectations might change. Computed tomography (CT) is often used to detect breast cancer’s spread, but this method has its weaknesses. The computer-assisted technique “radiomics” extracts grey-level patterns, so-called radiomic features, from medical images, which may reflect underlying biological processes. Our retrospective study therefore evaluated whether breast cancer spread can be predicted by radiomic features derived from iodine maps, an application on a new generation of CT scanners visualizing tissue blood flow. Based on 77 patients with newly diagnosed breast cancer, we found that this approach might indeed predict cancer spread to other organs/tissues. In the future, radiomics may serve as an additional tool for cancer detection and risk assessment.
Abstract: Dual-energy CT (DECT) iodine maps enable quantification of iodine concentrations as a marker for tissue vascularization. We investigated whether iodine map radiomic features derived from staging DECT enable prediction of breast cancer metastatic status, and whether textural differ- ences exist between primary breast cancers and metastases. Seventy-seven treatment-naïve patients with biopsy-proven breast cancers were included retrospectively (41 non-metastatic, 36 metastatic). Radiomic features including first-, second-, and higher-order metrics as well as shape descriptors were extracted from volumes of interest on iodine maps. Following principal component analysis, a multilayer perceptron artificial neural network (MLP-NN) was used for classification (70% of cases for training, 30% validation). Histopathology served as reference standard. MLP-NN predicted metastatic status with AUCs of up to 0.94, and accuracies of up to 92.6 in the training and 82.6 in the validation datasets. The separation of primary tumor and metastatic tissue yielded AUCs of up to 0.87, with accuracies of up to 82.8 in the training, and 85.7 in the validation dataset. DECT iodine map-based radiomic signatures may therefore predict metastatic status in breast cancer patients. In addition, microstructural differences between primary and metastatic breast cancer tissue may be reflected by differences in DECT radiomic features.
Simple Summary: Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge due to the lack of biomarkers indicating the optimal drug for each patient. This study analyzed blood samples of patients with predominant clear cell mRCC who were treated with the mTOR inhibitor everolimus after failure of one prior tumor therapy. In an exploratory approach, predictive blood biomarkers were searched. We found lower levels of the protein thrombospondin-2 (TSP-2) at the start of the therapy and higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation to be associated with therapy response. Of note, these blood biomarkers had a higher predictive value than baseline patient parameters or risk classifications. Polymorphisms in the mTOR gene appeared to be associated with therapy response, but were not significant. To conclude, it seems feasible to identify patients showing longtime responses to everolimus and possible to increase tumor therapy response rates based on biomarkers for individual therapy selection.
Abstract: There is an unmet need for predictive biomarkers in metastatic renal cell carcinoma (mRCC) therapy. The phase IV MARC-2 trial searched for predictive blood biomarkers in patients with predominant clear cell mRCC who benefit from second-line treatment with everolimus. In an exploratory approach, potential biomarkers were assessed employing proteomics, ELISA, and polymorphism analyses. Lower levels of angiogenesis-related protein thrombospondin-2 (TSP-2) at baseline (≤665 parts per billion, ppb) identified therapy responders with longer median progression-free survival (PFS; ≤665 ppb at baseline: 6.9 months vs. 1.8, p = 0.005). Responders had higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation (>27.14 nmol/L), associated with a longer median PFS (3.8 months vs. 2.2, p = 0.013) and improved overall survival (OS; 31.0 months vs. 14.0 months, p < 0.001). Baseline TSP-2 levels had a stronger relation to PFS (HR 0.36, p = 0.008) than baseline patient parameters, including IMDC score. Increased serum LDH levels two weeks after therapy initiation were the best predictor for OS (HR 0.21, p < 0.001). mTOR polymorphisms appeared to be associated with therapy response but were not significant. Hence, we identified TSP-2 and LDH as promising predictive biomarkers for therapy response on everolimus after failure of one VEGF-targeted therapy in patients with clear cell mRCC.
Falls from a height are a common cause of polytrauma care in Level I Trauma Centers worldwide. The expected injury consequences depend on the height of the fall and the associated acceleration, as well as the condition of the ground. In addition, we further hypothesize a correlation between the cause of the fall, the age of the patient, and the patient’s outcome. A total of 178 trauma patients without age restriction who were treated in our hospital after a fall >3 m within a 5-year period were retrospectively analyzed. The primary objective was a clinically and radiologically quantifiable increase in the severity of injuries after falls from different relevant heights (>3 m, >6 m, and >9 m). The cause of the fall, either accidental or suicidal; age and duration of intensive care unit stay, including duration of ventilation; and total hospital stay were analyzed. Additionally, the frequency of urgent operations, such as, external fixation of fractures or hemi-craniectomies, laboratory parameters; and clinical outcomes were also among the secondary objectives. Sustaining a thoracic trauma or pelvis fractures increases significantly with height, and vital parameters are significantly compromised. We also found significant differences in urgent pre- and in-hospital emergency interventions, as well as organ complications and outcome parameters depending on the fall’s height.
Vaginal breech delivery is becoming an extinct art although national guidelines underline its safety and vaginal breech delivery in an upright position has been shown to be a safe birth mode option. In order to spread clinical knowledge and be able to implement vaginal breech delivery into obstetricians’ daily practice, we need to gather knowledge from facilities who teach specialized obstetrical management. Methods: We performed a prospective cohort study on 140 vaginal deliveries out of breech presentation solely-managed by seven newly-trained physicians and compared fetal outcome as well as rates of manual assistance in respect to preexisting experience. Results: Fetal morbidity rate measured with a modified PREMODA score was not significantly different in three sub-cohorts sorted by preexisting expertise levels of managing obstetricians (experience groups EG, EG0: 2, 5%; EG1: 3, 7.5%; EG2: 1, 1.7%; p = 0.357). Manual assistance rate was significantly higher in EG1 (low experience level in breech delivery and only in dorsal position) compared to EG0 and EG2 (EG1 28, 70%; EG0: 14, 25%; EG2: 21, 35%; p = 0.0008). Conclusions: Our study shows that vaginal breech delivery with newly-trained obstetricians is a safe option whether or not they have advanced preexisting expertise in breech delivery. These data should encourage implementing vaginal breech delivery in clinical routine.
The plaque reduction neutralization test (PRNT) is a preferred method for the detection of functional, SARS-CoV-2 specific neutralizing antibodies from serum samples. Alternatively, surrogate enzyme-linked immunosorbent assays (ELISAs) using ACE2 as the target structure for the detection of neutralization-competent antibodies have been developed. They are capable of high throughput, have a short turnaround time, and can be performed under standard laboratory safety conditions. However, there are very limited data on their clinical performance and how they compare to the PRNT. We evaluated three surrogate immunoassays (GenScript SARS-CoV-2 Surrogate Virus Neutralization Test Kit (GenScript Biotech, Piscataway Township, NJ, USA), the TECO® SARS-CoV-2 Neutralization Antibody Assay (TECOmedical AG, Sissach, Switzerland), and the Leinco COVID-19 ImmunoRank™ Neutralization MICRO-ELISA (Leinco Technologies, Fenton, MO, USA)) and one automated quantitative SARS-CoV-2 Spike protein-based IgG antibody assay (Abbott GmbH, Wiesbaden, Germany) by testing 78 clinical samples, including several follow-up samples of six BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, NY, USA) vaccinated individuals. Using the PRNT as a reference method, the overall sensitivity of the examined assays ranged from 93.8 to 100% and specificity ranged from 73.9 to 91.3%. Weighted kappa demonstrated a substantial to almost perfect agreement. The findings of our study allow these assays to be considered when a PRNT is not available. However, the latter still should be the preferred choice. For optimal clinical performance, the cut-off value of the TECO assay should be individually adapted.
Sleep disordered breathing (SDB) is a frequent comorbidity in cardiac disease patients. Nevertheless, the prevalence and relationship between SDB and severe primary mitral regurgitation (PMR) has not been well investigated to date. Methods: A cohort of 121 patients with significant PMR undergoing mitral valve surgery were prospectively enrolled and received a cardiorespiratory single night polygraphy screening using ApneaLink before surgery. Eighty-two of them underwent a follow-up examination including a follow-up single-night sleep study 3 months after surgery. Results: The mean age of patients was 65.3 ± 12.0 years. Sixty patients (49.6%) were female. The mean EuroSCORE II was 2.5 ± 2.4%. Initially, 91 (75.2%) patients presented with SDB, among whom 50.4% (46 patients, 38.0% of total cohort) were classified as moderate to severe. These patients tended to require significantly longer postoperative intensive care and mechanical ventilation. Among the 82 patients who completed follow-up exams, mitral valve surgery led to a significant reduction in relevant SDB (20.7%). The apnea-hypopnea index (from 11/h [4;18] to 4/h [3;14] (p = 0.04)), the oxygenation-desaturation index (from 8/h [3;18] to 5/h [3;12] (p = 0.008)) as well as the saturation time below 90% (from 32 min [13;86] to 18 min [5;36] (p = 0.005)), were all shown to be improved significantly. Conclusion: The prevalence of SDB is very high in patients with severe primary mitral regurgitation and may contribute to postoperative complications and prolonged intensive care. A significantly reduced but still high prevalence of SDB was observed 3 months after mitral valve surgery, highlighting the bidirectional relationship between SDB and heart failure.
Drug interactions are a well-known cause of adverse drug events, and drug interaction databases can help the clinician to recognize and avoid such interactions and their adverse events. However, not every interaction leads to an adverse drug event. This is because the clinical relevance of drug–drug interactions also depends on the genetic profile of the patient. If inhibitors or inducers of drug metabolising enzymes (e.g., CYP and UGT) are added to the drug therapy, phenoconcversion can occur. This leads to a genetic phenotype that mismatches the observable phenotype. Drug–drug–gene and drug–gene–gene interactions influence the toxicity and/or ineffectivness of the drug therapy. To date, there have been limited published studies on the impact of genetic variations on drug–drug interactions. This review discusses the current evidence of drug–drug–gene interactions, as well as drug–gene–gene interactions. Phenoconversion is explained, the and methods to calculate the phenotypes are described. Clinical recommendations are given regarding the integratation of the PGx results in the assessment of the relevance of drug interactions in the future.
Sex differences in psychiatric comorbidity and clinical presentation in youths with conduct disorder
(2021)
Background: Conduct disorder (CD) rarely occurs alone but is typically accompanied by comorbid psychiatric disorders, which complicates the clinical presentation and treatment of affected youths. The aim of this study was to investigate sex differences in comorbidity pattern in CD and to systematically explore the ‘gender paradox’ and ‘delayed-onset pathway’ hypotheses of female CD.
Methods: As part of the FemNAT-CD multisite study, semistructured clinical interviews and rating scales were used to perform a comprehensive phenotypic characterization of 454 girls and 295 boys with CD (9–18 years), compared to 864 sex- and age-matched typically developing controls.
Results: Girls with CD exhibited higher rates of current major depression, anxiety disorders, post-traumatic stress disorder and borderline personality disorder, whereas boys with CD had higher rates of current attention-deficit/hyperactivity disorder. In line with the ‘gender paradox’ hypothesis, relative to boys, girls with CD showed significantly more lifetime psychiatric comorbidities (incl. Alcohol Use Disorder), which were accompanied by more severe CD symptoms. Female and male youths with CD also differed significantly in their CD symptom profiles and distribution of age-of-onset subtypes of CD (i.e. fewer girls with childhood-onset CD). In line with the ‘delayed-onset pathway’ hypothesis, girls with adolescent-onset CD showed similar levels of dimensional psychopathology like boys with childhood-onset CD, while boys with adolescent-onset CD had the lowest levels of internalizing psychopathology.
Conclusions: Within the largest study of CD in girls performed to date, we found compelling evidence for sex differences in comorbidity patterns and clinical presentation of CD. Our findings further support aspects of the ‘gender paradox’ and ‘delayed-onset pathway’ hypotheses by showing that girls with CD had higher rates of comorbid lifetime mental disorders and functional impairments, and they usually developed CD during adolescence. These novel data on sex-specific clinical profiles of CD will be critical in informing intervention and prevention programmes.
Aims: Somatic mutations in haematopoietic stem cells can lead to the clonal expansion of mutated blood cells, known as clonal haematopoiesis (CH). Mutations in the most prevalent driver genes DNMT3A and TET2 with a variant allele frequency (VAF) ≥ 2% have been associated with atherosclerosis and chronic heart failure of ischemic origin (CHF). However, the effects of mutations in other driver genes for CH with low VAF (<2%) on CHF are still unknown.
Methods and results: Therefore, we analysed mononuclear bone marrow and blood cells from 399 CHF patients by deep error-corrected targeted sequencing of 56 genes and associated mutations with the long-term mortality in these patients (3.95 years median follow-up). We detected 1113 mutations with a VAF ≥ 0.5% in 347 of 399 patients, and only 13% had no detectable CH. Despite a high prevalence of mutations in the most frequently mutated genes DNMT3A (165 patients) and TET2 (107 patients), mutations in CBL, CEBPA, EZH2, GNB1, PHF6, SMC1A, and SRSF2 were associated with increased death compared with the average death rate of all patients. To avoid confounding effects, we excluded patients with DNMT3A-related, TET2-related, and other clonal haematopoiesis of indeterminate potential (CHIP)-related mutations with a VAF ≥ 2% for further analyses. Kaplan–Meier survival analyses revealed a significantly higher mortality in patients with mutations in either of the seven genes (53 patients), combined as the CH-risk gene set for CHF. Baseline patient characteristics showed no significant differences in any parameter including patient age, confounding diseases, severity of CHF, or blood cell parameters except for a reduced number of platelets in patients with mutations in the risk gene set in comparison with patients without. However, carrying a mutation in any of the risk genes remained significant after multivariate cox regression analysis (hazard ratio, 3.1; 95% confidence interval, 1.8–5.4; P < 0.001), whereas platelet numbers did not.
Conclusions: Somatic mutations with low VAF in a distinct set of genes, namely, in CBL, CEBPA, EZH2, GNB1, PHF6, SMC1A, and SRSF2, are significantly associated with mortality in CHF, independently of the most prevalent CHIP-mutations in DNMT3A and TET2. Mutations in these genes are prevalent in young CHF patients and comprise an independent risk factor for the outcome of CHF, potentially providing a novel tool for risk assessment in CHF.
Background & Aims: HBV genotype G (HBV/G) is mainly found in co-infections with other HBV genotypes and was identified as an independent risk factor for liver fibrosis. This study aimed to analyse the prevalence of HBV/G co-infections in healthy European HBV carriers and to characterize the crosstalk of HBV/G with other genotypes.
Methods: A total of 560 European HBV carriers were tested via HBV/G-specific PCR for HBV/G co-infections. Quasispecies distribution was analysed via deep sequencing, and the clinical phenotype was characterized regarding qHBsAg-/HBV-DNA levels and frequent mutations. Replicative capacity and expression of HBsAg/core was studied in hepatoma cells co-expressing HBV/G with either HBV/A, HBV/D or HBV/E using bicistronic vectors.
Results: Although no HBV/G co-infection was found by routine genotyping PCR, HBV/G was detected by specific PCR in 4%-8% of patients infected with either HBV/A or HBV/E but only infrequently in other genotypes. In contrast to HBV/E, HBV/G was found as the quasispecies major variant in co-infections with HBV/A. No differences in the clinical phenotype were observed for HBV/G co-infections. In vitro RNA and DNA levels were comparable among all genotypes, but expression and release of HBsAg was reduced in co-expression of HBV/G with HBV/E. In co-expression with HBV/A and HBV/E expression of HBV/G-specific core was enhanced while core expression from the corresponding genotype was markedly diminished.
Conclusions: HBV/G co-infections are common in European inactive carriers with HBV/A and HBV/E infection, but sufficient detection depends strongly on the assay. HBV/G regulated core expression might play a critical role for survival of HBV/G in co-infections.
Background: A link between attention-deficit/hyperactivity disorder (ADHD) and alcohol use disorder (AUD) has been widely demonstrated. In this study, we used neuroimaging to investigate the connectivity traits that may contribute to the comorbidity of these disorders.
Methods: The study included an AUD group (N = 18), an ADHD group (N = 17), a group with AUD + ADHD comorbidity (N = 12) and a control group (N = 18). We used resting-state functional connectivity in a seed-based approach in the default mode networks, the dorsal attention network, and the salience network.
Results: Within the default mode networks, all affected groups shared greater connectivity toward the temporal gyrus when compared to the control group. Regarding the dorsal attention network, the Brodmann area 6 presented greater connectivity for each affected group in comparison with the control group, displaying the strongest aberrations in the AUD + ADHD group. In the salience network, the prefrontal cortex showed decreased connectivity in each affected group compared to the control group.
Conclusions: Despite the small and unequal sample sizes, our findings show evidence of common neurobiological alterations in AUD and ADHD, supporting the hypothesis that ADHD could be a risk factor for the development of AUD. The results highlight the importance of an early ADHD diagnosis and treatment to reduce the risk of a subsequent AUD.
Many proteins have been found to operate in a complex with various biomolecules such as proteins, nucleic acids, carbohydrates, or lipids. Protein complexes can be transient, stable or dynamic and their association is controlled under variable cellular conditions. Complexome profiling is a recently developed mass spectrometry-based method that combines mild separation techniques, native gel electrophoresis, and density gradient centrifugation with quantitative mass spectrometry to generate inventories of protein assemblies within a cell or subcellular fraction. This review summarizes applications of complexome profiling with respect to assembly ranging from single subunits to large macromolecular complexes, as well as their stability, and remodeling in health and disease.
It is well known that lifestyle changes can alter several physiological functions in the human body. For exercise and diet, these effects are used sensibly in basic therapies, as in cardiovascular diseases. However, the physiological changes induced by exercise and a modified diet also have the capacity to influence the efficacy and toxicity of several drugs, mainly by affecting different pharmacokinetic mechanisms. This pharmacological plasticity is not clinically relevant in all cases but might play an important role in altering the effects of very common drugs, particularly drugs with a narrow therapeutic window. Therefore, with this review, we provide insights into possible food–drug and exercise–drug interactions to sharpen awareness of the potential occurrence of such effects.
Background: Estimating prognosis of periodontally affected teeth at the beginning of supportive periodontal care (SPC) is an important component for further treatment planning. This study aimed to evaluate tooth loss (TL) during 10 years of SPC in periodontally compromised patients and to identify tooth-related factors affecting TL.
Methods: Patients were re-examined 120 ± 12 months after accomplishment of active periodontal therapy. TL was defined as primary outcome variable and tooth-related factors (abutment status, furcation involvement [FI], tooth mobility, mean periodontal probing depth [PD], and clinical attachment level [CAL] at beginning of SPC, and initial bone loss [BL]) were estimated based on an adjusted regression analyses model.
Results: Ninety-seven patients (51 females and 46 males; mean age, 65.3 ± 11 years) lost 119 of 2,323 teeth (overall TL [OTL]: 0.12 teeth/patient/y) during 10 years of SPC. Forty of these teeth (33.6%) were lost for periodontal reasons (TLP; 0.04 teeth/patient/y). Significantly more teeth were lost due to other reasons (P <0.0001). TLP (OTL) only occurred in 5.9% (14.7%) of all teeth, when BL was at least 80%. Use as abutment tooth, FI degree III, tooth mobility degrees I and II, mean PD, and CAL positively correlated with OTL (P <0.05). For TLP, FI and tooth mobility degree III as well as mean CAL were identified as tooth-related prognostic factors (P <0.05).
Conclusions: During 10 years of SPC, most of the teeth (93.4%) of periodontally compromised patients were retained, showing the positive effect of a well-established treatment concept. Well-known tooth-related prognostic factors were confirmed.
The prevalence of peri-implant diseases around subcrestally placed implants: a cross-sectional study
(2021)
Objectives: To evaluate the prevalence of peri-implant health, peri-implant mucositis or periimplantitis for subcrestally placed implants (1–3 mm) on the short-, medium- and long term.
Material and Methods: Two hundred patients were enrolled in this cross-sectional study that were treated and screened during regular maintenance visits at one university center. A total of 657 implants were evaluated. Peri-implant health and diseases were assessed according to predefined case definitions. Binary logistic regression was used to assess the correlation with local and systemic factors.
Results: After a median function time of 9.36 ± 6.44 years (range: 1–26 years), the prevalence of peri-implant mucositis and peri-implantitis was 66.5% and 15.0%, at the patient level, corresponding to 62.6% and 7.5%, at the implant level, respectively. Peri-implantitis was significantly associated with patients’ history of periodontitis (odds ratio, OR 5.33).
Conclusion: Peri-implant diseases were a common finding around subcrestally placed implants.
Over the past years, next-generation sequencing (NGS) technologies revolutionized the possibilities in a broad range of application areas. Also in the field of forensic genetics, NGS continuously gained in importance and attentiveness. A significant number of sudden cardiac deaths (SCD) in the young is due to heritable arrhythmia syndromes emphasizing the need of examining the genetic basis in these cases also with regard to the identification of relatives and/or patients being at risk. As a result, high-throughput methods became of increasing value in molecular autopsy investigations enabling the analysis of a broad spectrum of genes.
Most standard protocols are optimized for high-quality samples and frequently not directly applicable to challenging forensic sample material. In the present study, we intended to examine a comprehensive gene panel associated with SCD and inherited arrhythmogenic disorders. We compared three different hybridization-based library preparation technologies in order to implement a suitable NGS workflow for heterogeneous, forensic as well as diagnostic sample material.
The results obtained indicated, that the Illumina technologies Nextera DNA Flex and TruSeq were compatible with samples exhibiting varying levels of degradation. In comparison, the TruSight method also resulted in good sequencing data, but seemed to be more dependent on DNA integrity. The preparation protocols evaluated in our study are not restricted to molecular autopsy investigations and might be helpful for and transferrable to further forensic research applications.
Interactions of drugs with the classical epigenetic mechanism of DNA methylation or histone modification are increasingly being elucidated mechanistically and used to develop novel classes of epigenetic therapeutics. A data science approach is used to synthesize current knowledge on the pharmacological implications of epigenetic regulation of gene expression. Computer-aided knowledge discovery for epigenetic implications of current approved or investigational drugs was performed by querying information from multiple publicly available gold-standard sources to (i) identify enzymes involved in classical epigenetic processes, (ii) screen original biomedical scientific publications including bibliometric analyses, (iii) identify drugs that interact with epigenetic enzymes, including their additional non-epigenetic targets, and (iv) analyze computational functional genomics of drugs with epigenetic interactions. PubMed database search yielded 3051 hits on epigenetics and drugs, starting in 1992 and peaking in 2016. Annual citations increased to a plateau in 2000 and show a downward trend since 2008. Approved and investigational drugs in the DrugBank database included 122 compounds that interacted with 68 unique epigenetic enzymes. Additional molecular functions modulated by these drugs included other enzyme interactions, whereas modulation of ion channels or G-protein-coupled receptors were underrepresented. Epigenetic interactions included (i) drug-induced modulation of DNA methylation, (ii) drug-induced modulation of histone conformations, and (iii) epigenetic modulation of drug effects by interference with pharmacokinetics or pharmacodynamics. Interactions of epigenetic molecular functions and drugs are mutual. Recent research activities on the discovery and development of novel epigenetic therapeutics have passed successfully, whereas epigenetic effects of non-epigenetic drugs or epigenetically induced changes in the targets of common drugs have not yet received the necessary systematic attention in the context of pharmacological plasticity.
Epoxides and diols of polyunsaturated fatty acids (PUFAs) are bioactive and can influence processes such as tumor cell proliferation and angiogenesis. Studies with inhibitors of the soluble epoxide hydrolase (sEH) in animals overexpressing cytochrome P450 enzymes or following the systemic administration of specific epoxides revealed a markedly increased incidence of tumor metastases. To determine whether PUFA epoxides increased metastases in a model of spontaneous breast cancer, sEH-/- mice were crossed onto the polyoma middle T oncogene (PyMT) background. We found that the deletion of the sEH accelerated the growth of primary tumors and increased both the tumor macrophage count and angiogenesis. There were small differences in the epoxide/diol content of tumors, particularly in epoxyoctadecamonoenic acid versus dihydroxyoctadecenoic acid, and marked changes in the expression of proteins linked with cell proliferation and metabolism. However, there was no consequence of sEH inhibition on the formation of metastases in the lymph node or lung. Taken together, our results confirm previous reports of increased tumor growth in animals lacking sEH but fail to substantiate reports of enhanced lymph node or pulmonary metastases.
Objectives: Bladder neck contracture (BNC) is a bothersome complication following endoscopic treatment for benign prostatic hyperplasia (BPH). The objective of our study was to give a more realistic insight into contemporary endoscopic BNC treatment and to evaluate and identify risk factors associated with inferior outcome. Material and Methods: We identified patients who underwent transurethral treatment for BNC secondary to previous endoscopic therapy for BPH between March 2009 and October 2016. Patients with vesico-urethral anastomotic stenosis after radical prostatectomy were excluded. Digital charts were reviewed for re-admissions and re-visits at our institutions and patients were contacted personally for follow-up. Our non-validated questionnaire assessed previous urologic therapies (including radiotherapy, endoscopic, and open surgery), time to eventual further therapy in case of BNC recurrence, and the modality of recurrence management. Results: Of 60 patients, 49 (82%) and 11 (18%) underwent transurethral bladder neck resection and incision, respectively. Initial BPH therapy was transurethral resection of the prostate (TURP) in 54 (90%) and holmium laser enucleation of the prostate (HoLEP) in six (10%) patients. Median time from prior therapy was 8.5 (IQR 5.3–14) months and differed significantly in those with (6.5 months; IQR 4–10) and those without BNC recurrence (10 months; IQR 6–20; p = 0.046). Thirty-three patients (55%) underwent initial endoscopic treatment, and 27 (45%) repeated endoscopic treatment for BNC. In initially-treated patients, time since BPH surgery differed significantly between those with a recurrence (median 7.5 months; IQR 6–9) compared to those treated successfully (median 12 months; IQR 9–25; p = 0.01). In patients with repeated treatment, median time from prior BNC therapy did not differ between those with (4.5 months; IQR 2–12) and those without a recurrence (6 months; IQR 6–10; p = 0.6). Overall, BNC treatment was successful in 32 patients (53%). The observed success rate of BNC treatment was significantly higher after HoLEP compared to TURP (100% vs. 48%; p = 0.026). Type of BNC treatment, number of BNC treatment, and age at surgery did not influence the outcome. Conclusions: A longer time interval between previous BPH therapy and subsequent BNC incidence seems to favorably affect treatment success of endoscopic BNC treatment, and transurethral resection and incision appear equally effective. Granted the relatively small sample size, BNC treatment success seems to be higher after HoLEP compared to TURP, which warrants validation in larger cohorts.
Purpose: To stratify differences in visual semantic and quantitative imaging features in intensive care patients with nonspecific mastoid effusions versus patients with acute mastoiditis (AM) requiring surgical treatment. Methods: We included 48 patients (male, 28; female, 20; mean age, 59.5 ± 18.1 years) with mastoid opacification (AM, n = 24; control, n = 24) who underwent clinically indicated cerebral CT between 12/2007 and 07/2018 in this retrospective study. Semantic features described the extend and asymmetry of mastoid and middle-ear cavity opacification and complications like erosive changes. Minimum, maximum and mean Hounsfield unit (HU) values were obtained as quantitative features. We analyzed the features employing univariate testing. Results: Compared to intensive care patients, AM patients revealed asymmetric mastoid or middle-ear cavity opacification (likelihood-ratio (LR) < 0.001). Applying a dedicated threshold of the extent of opacification, AM patients reached significance levels of LR = 0.042 and 0.002 for mastoid and middle-ear cavity opacification. AM cases showed higher maximum and mean HU values (p = 0.009, p = 0.024). Conclusions: We revealed that the extent and asymmetry of mastoid and middle-ear cavity opacification differs significantly between AM patients and intensive care patients. Multicenter research is needed to expand our cohort and possibly pave the way to build a non-invasive predictive model for AM in the future.